Published in final edited form as:

J Perinat Med. 2016 January ; 44(1): 77–98. doi:10.1515/jpm-2015-0103.

Clinical Chorioamnionitis IV: the Maternal Plasma Cytokine Profile

Roberto Romero, MD, D.Med.Sci.^{1,2,3,4}, Piya Chaemsathong, MD^{1,5}, Nikolina Docheva, BMBS^{1,5}, Steven J. Korzeniewski, PhD^{1,3,5}, Adi L. Tarca, PhD^{1,5}, Gaurav Bhatti^{1,5}, Zhonghui Xu^{1,5}, Juan P. Kusanovic, MD^{1,6,7}, Zhong Dong, PhD^{1,5}, Ahmed I. Ahmed, MD^{1,5}, Bo Hyun Yoon, MD, PhD^{1,8}, Sonia S. Hassan, MD^{1,5}, Tinnakorn Chaiworapongsa, MD^{1,5}, and Lami Yeo, MD^{1,5}

¹Perinatology Research Branch, Program for Perinatal Research and Obstetrics, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, MD and Detroit, MI, USA

²Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI, USA

³Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, MI, USA

⁴Department of Molecular Obstetrics and Genetics, Wayne State University, Detroit, MI, USA

⁵Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, MI, USA

⁶Center for Research and Innovation in Maternal-Fetal Medicine (CIMAF). Department of Obstetrics and Gynecology, Sótero del Río Hospital, Santiago, Chile

⁷Department of Obstetrics and Gynecology, Pontificia Universidad Católica de Chile, Santiago, Chile

⁸Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea

Abstract

Introduction—Fever is a major criterion for clinical chorioamnionitis; yet, many patients with intrapartum fever do not have demonstrable intra-amniotic infection. Some cytokines, such as interleukin (IL)-1, IL-6, interferon-gamma (IFN- γ) and tumor necrosis factor-alpha (TNF- α) can induce a fever. The objective of this study was to determine whether maternal plasma concentrations of cytokines could be of value in the identification of patients with the diagnosis of clinical chorioamnionitis at term who have microbial-associated intra-amniotic inflammation.

Methods—A retrospective cross-sectional study was conducted, including patients with clinical chorioamnionitis at term (n=41; cases) and women in spontaneous labor at term without clinical chorioamnionitis (n=77; controls). Women with clinical chorioamnionitis were classified into three groups according to the results of amniotic fluid cultures, broad-range polymerase chain reaction

coupled with electrospray ionization mass spectrometry (PCR/ESI-MS), and amniotic fluid IL-6 concentrations: 1) no intra-amniotic inflammation; 2) intra-amniotic inflammation without detectable microorganisms; or 3) microbial-associated intra-amniotic inflammation. The maternal plasma concentrations of 29 cytokines were determined with sensitive and specific V-PLEX immunoassays. Nonparametric statistical methods were used for analysis, adjusting for a false discovery rate of 5%.

Results—1) The maternal plasma concentrations of pyrogenic cytokines (IL-1 β , IL-2, IL-6, IFN- γ and TNF- α) were significantly higher in patients with clinical chorioamnionitis at term than in those with spontaneous term labor without clinical chorioamnionitis; 2) the maternal plasma concentrations of cytokines were not significantly different among the three subgroups of patients with clinical chorioamnionitis (intra-amniotic inflammation with and without detectable bacteria and those without intra-amniotic inflammation); and 3) among women with the diagnosis of clinical chorioamnionitis, but without evidence of intra-amniotic inflammation, the maternal plasma concentrations of pyrogenic cytokines were significantly higher than in patients with spontaneous labor at term. These observations suggest that the fever can be mediated by increased circulating concentrations of these cytokines, despite the absence of a local intra-amniotic inflammatory response.

Conclusions—1) The maternal plasma concentrations of pyrogenic cytokines (e.g. IL-1 β , IL-2, IL-6, IFN- γ and TNF- α) are higher in patients with intra-partum fever and the diagnosis of clinical chorioamnionitis at term than in those in spontaneous labor at term without a fever; and 2) maternal plasma cytokine concentrations have limited value in the identification of patients with bacteria in the amniotic cavity. Accurate assessment of the presence of intra-amniotic infection requires amniotic fluid analysis.

Keywords

Acute histologic chorioamnionitis; amniotic fluid; biomarkers; chemokines; fever; funisitis; interferon-gamma (IFN- γ); interleukin-1 beta (IL-1 β); interleukin-2 (IL-2); interleukin-6 (IL-6); microbial-associated intra-amniotic inflammation; pyrogens; tumor necrosis factor-alpha (TNF- α); V-PLEX immunoassays

Introduction

Clinical chorioamnionitis is characterized by maternal fever accompanied by at least two of the following signs: maternal or fetal tachycardia, maternal leukocytosis, uterine tenderness, or foul-smelling amniotic fluid [1–13]. This pregnancy complication is associated with adverse maternal [14–19], fetal, and neonatal/infant outcomes [20–40]. Most of the signs of clinical chorioamnionitis (except for fetal tachycardia and foul-smelling amniotic fluid) are thought to reflect a maternal inflammatory response to microbial invasion of the amniotic cavity (MIAC) [1,7]. Fever, the cardinal sign of clinical chorioamnionitis, is mediated by the effect of pyrogenic cytokines [41–43], which include interleukin (IL)-1 [43–51], IL-2 [52–54], IL-6 [55–59], interferon-gamma IFN- γ [60,61] and tumor necrosis factor-alpha (TNF- α) [54,62–65]. Some of these cytokines have primary pyrogenic effects, i.e. IL-1 [43–51] or TNF- α [54,62–65], while others induce fever indirectly, i.e. IL-2 [52–54]. Fever can be generated independently of IL-1 and TNF- α by the engagement of Toll-like receptors [66–

70]. These different pathways converge in the production of cyclooxygenase-2 [69–73] and prostaglandin E₂ [74–80], which bind to prostanoid receptors in the hypothalamus [43,70]. Thermosensitive neurons in the thermoregulatory center then raise the hypothalamic thermostatic set-point [69,81,82].

Many cases of intra-partum fever are not related to infection [9,12,83–91]. We recently reported that only 54% of women with clinical chorioamnionitis (all had fever) at term had microorganisms isolated from the amniotic cavity; 24% had intra-amniotic inflammation without demonstrable bacteria, and 22% had no intra-amniotic inflammation [9]. Epidural analgesia can cause maternal hyperthermia in the absence of intra-amniotic infection [83,86,92–107]. Therefore, when patients have a fever, the accurate diagnosis of infection is challenging, but important. We recently reported that the signs used in the diagnosis of clinical chorioamnionitis do not accurately identify patients with proven intra-amniotic infection [4].

The objective of this study was to determine if the maternal plasma concentration of cytokines could distinguish patients with clinical chorioamnionitis with and without proven intra-amniotic infection.

Materials and Methods

Study population

A retrospective cross-sectional case-control study was conducted by searching the clinical database and Bank of Biological Materials of Wayne State University, the Detroit Medical Center, and the Perinatology Research Branch (NICHD/NIH/DHHS). The inclusion criteria were: 1) singleton gestation; 2) gestational age $\geq$ 37 weeks; and 3) the absence of fetal malformations.

Cases consisted of women with clinical chorioamnionitis at term (n=41). These women had also been included in a prior study that provided a detailed description of sample collection, microbiological studies, and determination of amniotic fluid IL-6 concentrations using a sensitive and specific enzyme-linked immunosorbent assay [9]. Controls were women with spontaneous term labor without clinical and histological chorioamnionitis (n=77; gestational age of 37–42 weeks).

All patients provided written informed consent, and the use of biological specimens as well as clinical and ultrasound data for research purposes was approved by the Institutional Review Boards of NICHD, Wayne State University and Sótero del Río Hospital, Santiago, Chile.

Clinical definitions

MIAC was defined according to the results of amniotic fluid culture and broad-range polymerase chain reaction coupled with electrospray ionization mass spectrometry (PCR/ESI-MS), (Ibis® Technology, Athogen, Carlsbad, CA) [108–111]. Intra-amniotic inflammation was diagnosed when the amniotic fluid IL-6 concentration was $\geq$ 2.6 ng/mL [10,112–125]. Based on the results of amniotic fluid cultures, PCR/ESI-MS, and amniotic

fluid concentrations of IL-6, patients with clinical chorioamnionitis at term were classified as having: 1) no intra-amniotic inflammation; 2) intra-amniotic inflammation without detectable bacteria (an elevated amniotic fluid IL-6 concentration without evidence of bacteria using cultivation and molecular microbiological methods); or 3) microbial-associated intra-amniotic inflammation (a combination of MIAC and intra-amniotic inflammation). Clinical chorioamnionitis was diagnosed by the presence of maternal fever (temperature > 37.8°C) accompanied by two or more of the following criteria: 1) maternal tachycardia (heart rate > 100 beats/min); 2) uterine tenderness; 3) foul-smelling amniotic fluid; 4) fetal tachycardia (heart rate > 160 beats/min); and 5) maternal leukocytosis (leukocyte count > 15,000 cells/mm³) [3,4,7,8,126,127].

Controls were women with spontaneous labor without clinical or histological chorioamnionitis, who delivered a normal term (> 37 weeks) infant whose birthweight was appropriate for the gestational age (10th–90th percentile) [128,129].

Acute histologic chorioamnionitis was diagnosed based on the presence of inflammatory cells in the chorionic plate and/or chorioamniotic membranes [130–139]. Acute funisitis was diagnosed based on the presence of neutrophils in the wall of the umbilical vessels and/or Wharton's jelly, using criteria previously described [130,140–145]. Acute inflammatory lesions of the placenta or placental lesions consistent with amniotic fluid infection were defined by the presence of acute histologic chorioamnionitis and/or acute funisitis [130].

Sample collection and cytokine/chemokine immunoassays

Maternal blood samples were collected at admission during labor in both cases and controls. These samples were placed into tubes containing EDTA, then centrifuged for 10 minutes at 4°C and stored at –70°C. Laboratory personnel were blinded to the clinical diagnosis. The maternal plasma concentrations of the following 29 cytokines/chemokines were determined with sensitive and specific V-PLEX immunoassays (Meso Scale Discovery, Gaithersburg, MD, USA) [*Pro-inflammatory cytokines*: IFN- γ , interleukin IL-1 α , IL-1 β , IL-2, IL-6, IL-7, IL-12p70, IL-12/IL-23p40, IL-15, IL-16, IL-17 α , TNF- α , TNF- β , vascular endothelial growth factor (VEGF), granulocyte macrophage colony-stimulating factor (GM-CSF); *anti-inflammatory cytokines*: IL-4, IL-5, IL-10, IL-13; and *chemokines*: IL-8, thymus and activation-regulated chemokine (TARC), eotaxin, eotaxin-3, macrophage-derived chemokine (MDC), macrophage inflammatory protein (MIP)-1 α , MIP-1 β , monocyte chemoattractant protein (MCP)-1, MCP-4, C-X-C motif chemokine 10 (CXCL-10) or IFN- γ -induced protein 10 (IP-10)]. Briefly, 50 μ L of a maternal blood sample or calibrator were dispensed into separate wells of the plates and incubated for 2 hours with vigorous shaking at room temperature. The samples and calibrators were discarded, and the plates were washed three times with phosphate-buffered saline and 0.05% Tween-20, followed by the addition of 25 μ L of the 1 $\times$ detection antibody solution into each well. Plates were then incubated for 2 hours with vigorous shaking at room temperature. The detection antibody was removed, and the plates were washed three times. One hundred and fifty microliters of 2 $\times$ Read Buffer T were added to each well, and the signals were read by the SECTOR® Imager 2400 (Meso Scale Discovery). Standard curves were generated, and the assay values of the samples were interpolated from the curves. The assay characteristics are described in the Supplementary

Table. The coefficient of variation was 14.6% for 20 of the 29 analytes. For samples with concentrations below the limits of detection, missing values were replaced with 99% of the lowest detectable concentration.

Statistical analysis

For demographics data analysis: the Kolmogorov-Smirnov test was used to test whether the distribution of continuous variables was normal. Chi-square and Fisher's exact tests were used for comparisons of proportions. The Kruskal-Wallis and Mann-Whitney *U* tests were used to compare median concentrations of analytes between and among groups. Statistical analysis of demographics data was performed using SPSS 19 (IBM Corp, Armonk, NY, USA). A *p*-value < 0.05 was considered statistically significant.

Comparison of analyte concentrations determined by multiplex assay was restricted to the analytes detected in a number of samples larger than one-half of the size of the smallest group. Statistical analysis was performed using the Wilcoxon rank-sum test and R statistical environment [146]. Nominal *p*-values were adjusted using the Benjamini and Hochberg method [147], controlling the false discovery rate at 5%.

Results

Characteristics of the study population

Clinical characteristics of the study population are displayed in Table 1. Patients with clinical chorioamnionitis had a significantly lower median maternal age than those with spontaneous term labor without clinical chorioamnionitis (*p*=0.007). Otherwise, there were no significant differences in the clinical characteristics between these two groups. All patients with clinical chorioamnionitis received epidural analgesia.

When classified according to the presence or absence of both intra-amniotic inflammation and microorganisms (by amniotic fluid cultures and PCR/ESI-MS), 58.5% (24/41) of the cases had microbial-associated intra-amniotic inflammation, 22% (9/41) had intra-amniotic inflammation without demonstrable bacteria and 19.5% (8/41) had no evidence of intra-amniotic inflammation. The microorganisms identified in the amniotic fluid were previously reported [9]. A placental histopathology report was not available for one patient with clinical chorioamnionitis. Acute inflammatory lesions of the placenta were found in 62.5% (25/40) of patients with clinical chorioamnionitis. Among cases with intra-amniotic inflammation with and without demonstrable microorganisms, 79.2% (19/24) and 62.5% (5/8) had acute inflammatory lesions of the placenta, respectively. Only 12.5% (1/8) of cases without intra-amniotic inflammation had acute inflammatory lesions of the placenta.

Maternal plasma cytokine and chemokine concentrations in clinical chorioamnionitis at term and spontaneous term labor without clinical chorioamnionitis

Clinical chorioamnionitis vs. spontaneous labor at term without clinical chorioamnionitis—The maternal plasma cytokine and chemokine concentrations of women with spontaneous labor at term and those with clinical chorioamnionitis at term are described in Table 2. Women with clinical chorioamnionitis had significantly higher median

maternal plasma concentrations of 10/19 inflammation-related cytokines than the controls (after correcting for false discovery). The fold difference in median maternal plasma concentrations of IL-2, IL-6, IL-1 β , IL-17 α , IFN- γ , TNF- β , TNF- α , IL-15, IL-12/IL-23p40, IL-10, and IL-5 ranged from 1.17 to 13.13. IL-2 had the greatest fold change of 13.13 (Table 2). Importantly, the maternal plasma concentrations of several pyrogenic cytokines (IL-6, IL-2, TNF- α , and IL-1 β) were higher in women with clinical chorioamnionitis (all with a fever) than in those with spontaneous labor at term without clinical chorioamnionitis.

Patients with clinical chorioamnionitis at term had significantly higher median maternal plasma concentrations of three out of the 10 chemokines (MCP-1, MIP-1 α , and IL-8) than the controls, with a fold difference in the median approximately of 1.2 for the three of them. Eotaxin, MCP-4, and eotaxin-3 were significantly lower in women with clinical chorioamnionitis than in the controls, and fold differences in the median were 0.83, 0.70, and 0.24, respectively (Table 2).

Maternal plasma cytokine concentrations in patients with clinical chorioamnionitis according to the presence of inflammation and bacteria in the amniotic fluid

In this study, six out of the 10 pro-inflammatory cytokines (IL-6, IL-2, IFN- γ , TNF- α , IL-17 α and IL-15) had significantly higher concentrations in cases without intra-amniotic inflammation than in the controls, and fold differences in the median ranged from 1.82 to 18.69 (Table 3). IL-2 and IFN- γ had fold changes >15 when comparing cases without intra-amniotic inflammation to women in spontaneous labor at term (Figures 1 and 2). IL-6 was the only pro-inflammatory cytokine that was significantly higher in cases with intra-amniotic inflammation without demonstrable microorganisms than in those with spontaneous labor at term (Figure 3).

Patients with clinical chorioamnionitis and microbial-associated intra-amniotic inflammation had significantly higher median maternal plasma concentrations of IL-2, IL-6, and IL-15 than those with spontaneous labor at term, with fold changes of 13.13, 6.16, and 1.26, respectively (Table 3). IFN- γ had a fold change >15, and the difference was detected only in the subgroup of clinical chorioamnionitis without intra-amniotic inflammation but not in those with intra-amniotic inflammation, when compared to the controls. In contrast, maternal IL-6 concentrations were significantly higher in all subgroups with clinical chorioamnionitis than in the control group (i.e. clinical chorioamnionitis without intra-amniotic inflammation: fold change 2.66, $p=0.008$; clinical chorioamnionitis with intra-amniotic inflammation without demonstrable bacteria: fold change 3.85, $p=0.009$; clinical chorioamnionitis with microbial-associated intra-amniotic inflammation: fold change 6.16, $p=0.0000025$; Table 3; Figure 3).

Among the four anti-inflammatory cytokines, the median maternal plasma IL-10 concentration was four times greater in women with chorioamnionitis without intra-amniotic inflammation than in the controls (Table 3). However, the difference did not reach statistical significance in cases with intra-amniotic inflammation with or without detectable microorganisms, when each one was compared to the controls (Table 3).

Patients with clinical chorioamnionitis without intra-amniotic inflammation had significantly higher maternal plasma CXCL-10 (or IP-10) concentrations than the controls (fold change=2.11; $p=0.02$) (Table 3). Eotaxin-3 is the only chemokine that had a significantly lower concentration in cases of intra-amniotic inflammation without demonstrable microorganisms than in the controls (fold change=0.24; $p=0.008$). The concentration of MCP-4 and eotaxin-3 were significantly lower in cases with microbial-associated intra-amniotic inflammation than in the controls (eotaxin-3: fold change=0.20, $p=0.003$; MCP-4: fold change=0.59, $p=0.003$; Table 3). Overall, no differences could be detected in the maternal plasma concentrations of cytokines among the subgroups of patients with clinical chorioamnionitis at term (Table 3).

The supplementary material contains the scatterplots of maternal plasma concentrations of cytokines/chemokines among the different groups (Supplementary Figures 1–3).

Discussion

Principal findings of this study

1) The maternal plasma concentrations of pyrogenic cytokines (IL-1 β , IL-2, IL-6, IFN- γ , TNF- α) were significantly higher in patients with clinical chorioamnionitis at term than in those with spontaneous term labor without clinical chorioamnionitis; 2) the maternal plasma concentrations of cytokines were not significantly different among the three subgroups of patients with clinical chorioamnionitis (intra-amniotic inflammation with and without detectable bacteria, and those without intra-amniotic inflammation); and 3) among women with the diagnosis of clinical chorioamnionitis, but without evidence of intra-amniotic inflammation, the maternal plasma concentrations of pyrogenic cytokines were significantly higher than in women with spontaneous labor at term. These observations suggest that the intra-amniotic inflammatory response observed in some patients with clinical chorioamnionitis is not reflected in the maternal circulation.

Maternal plasma cytokines in patients with clinical chorioamnionitis

Intra-amniotic inflammation and bacteria are frequently present in patients with clinical chorioamnionitis at term [1,3,7,9,12] and other complications of pregnancy, such as preterm labor [13,116,119,148–164], preterm prelabor rupture of the membranes (PPROM) [109,117,121,135,165–176], cervical insufficiency [177–179], and in patients with an asymptomatic short cervix [118,180–185]. Microorganisms and their products can initiate an inflammatory response by the engagement of pattern recognition receptors [163,172,186–200] and the production of cytokines [112,122,151,201–224], chemokines [213,215,216,219,223,225–244], prostaglandins [245–261] and proteases [142,145,262–277]. If microorganisms in the amniotic cavity reach the fetus, this can result in a fetal systemic inflammatory response [278,279], which is associated with multi-organ involvement [141,278,280–289], and preterm delivery [290].

We report herein, for the first time, a systematic study of the maternal cytokine profile using multiplex immunoassays in patients with clinical chorioamnionitis at term stratified according to the status of the amniotic cavity (presence/absence of inflammation and

bacteria). The results showed that clinical chorioamnionitis at term is associated with higher maternal plasma pro- and anti-inflammatory cytokines, as well as some chemokines, than in patients with spontaneous labor at term without a fever. The greatest fold change was observed in the maternal plasma concentration of IL-2, followed by IL-6 (13.13 vs 4.32, respectively). Other cytokines and chemokines had fold changes of a lesser magnitude (<5).

IL-2 is a lymphocyte growth factor involved in the differentiation of CD4⁺ and CD8⁺ cells, as well as immune tolerance [291–296], and it has been implicated in the pathogenesis of sepsis [297–300]. Therapeutic administration of IL-2 to patients with cancer can lead to a sepsis-like syndrome [301–303]. *In vitro* and *in vivo* studies have shown that IL-2 up-regulates the production of IL-1 β and TNF- α in peripheral blood mononuclear cells [52,304], which are also involved in the pathogenesis of sepsis [305,306]. Moreover, IL-2 administration is associated with the activation of complement [307–311], neutrophils [311,312], and the coagulation system [313]. Circulating IL-2 receptor concentrations can also predict the likelihood of sepsis in both newborns [314] and adults [315–317].

Maternal inflammatory response in clinical chorioamnionitis without intra-amniotic inflammation

We have previously reported that a subset of patients with clinical chorioamnionitis at term did not have intra-amniotic inflammation [9] and that their amniotic fluid inflammatory response was similar to that of women with spontaneous labor at term without fever or complications [12]. In the current study, patients with clinical chorioamnionitis without intra-amniotic inflammation had higher concentrations of several maternal plasma cytokines (e.g. IL-2, IFN- γ , IL-6, TNF- α , IL-17 α , and IL-15) than patients with spontaneous term in labor. Of interest, the maternal plasma IL-2 and IFN- γ concentrations had a fold change >15 in patients with clinical chorioamnionitis without intra-amniotic inflammation when compared to the controls. Of note, IFN- γ was significantly higher only in patients with clinical chorioamnionitis without intra-amniotic inflammation, but not in those with intra-amniotic inflammation either with or without demonstrable bacteria, when each was compared to the controls (spontaneous labor at term without a fever).

IFN- γ is a potent pro-inflammatory cytokine with anti-viral properties [318,319]. The administration of IFN- γ in patients with cancer can induce a fever [320,321]. However, the pyrogenic effect appears to be due to the induction of IL-1 and TNF- α [60,322,323]. The administration of IFN- γ to human subjects initiates fever 3–4 hours after injection [53].

Therefore, the fever of some patients with the diagnosis of clinical chorioamnionitis may be mediated by IFN- γ or other pyrogenic cytokines.

Maternal plasma cytokines in patients with intra-amniotic inflammation with or without bacteria in the amniotic cavity

We observed a dramatic elevation in the concentration of maternal plasma IL-6 (fold change >5) in patients with bacteria in the amniotic cavity. This is not unexpected, as this cytokine is a major mediator of the host response to infection and tissue damage [324–328]. Bacterial products are known to up-regulate the expression of IL-6 [329,330] and so are other inflammatory cytokines elevated in cases of intra-amniotic infection [329,330]. Despite the

large magnitude of the elevation in maternal plasma IL-6, we are not persuaded that this information can be used to distinguish between patients with and without infection in the amniotic cavity. This is in keeping with the observations of others [331,332]. The most likely explanation for this is that IL-6 is a mediator of the acute phase response; therefore, its concentration is elevated in the presence of an inflammatory insult unrelated to infection [87,333,334]. For example, the maternal plasma concentration of IL-6 is elevated in patients with spontaneous labor at term [335–344] without proven infection, which was assessed by amniotic fluid analysis.

In contrast to maternal plasma, amniotic fluid IL-6 concentrations are of value in the identification of the patient at risk for preterm delivery [112,116–119,122,123,169,211,212] or neonatal complications [112,116,119,122,123,214,345,346], and they are superior to amniotic fluid white blood cell counts, glucose concentrations, or Gram stains [331,347–353]. Recent studies suggest that amniotic fluid IL-6 is equivalent to other techniques, such as proteomic analysis of amniotic fluid [353], and rapid assays are now available that provide results within 20 minutes [120,124,125,354–356]. These assays allow IL-6 to be used as a point-of-care test [120,124,125,354–356].

Conclusion

We demonstrate, for the first time, that patients with clinical chorioamnionitis at term have higher maternal plasma concentrations of pyrogenic cytokines identified thus far (IL-1 β , IL-2, IL-6, IFN- γ , TNF- α) than patients in spontaneous labor at term without a fever. However, among patients with clinical chorioamnionitis, the absolute concentration of cytokines cannot be used to identify those who have bacteria in the amniotic fluid. This suggests that amniotic fluid assessment is required to identify intra-amniotic inflammation. Recently, a transcervical amniotic fluid collector was described that showed promising results in the analysis of the amniotic fluid in patients with PPRM [357]. This device may be of value to a subset of patients who will benefit from anti-inflammatory or antibiotic treatment.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This research was supported, in part, by the Perinatology Research Branch, Program for Perinatal Research and Obstetrics, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, U.S. Department of Health and Human Services (NICHD/NIH/DHHS) and, in part, with Federal funds from NICHD/NIH/DHHS under Contract No. HHSN275201300006C.

References

1. Gibbs RS. Diagnosis of intra-amniotic infection. *Semin Perinatol.* 1977; 1:71–77. [PubMed: 106471]
2. Gibbs RS, Castillo MS, Rodgers PJ. Management of acute chorioamnionitis. *Am J Obstet Gynecol.* 1980; 136:709–713. [PubMed: 7355955]

3. Gibbs RS, Blanco JD, St Clair PJ, et al. Quantitative bacteriology of amniotic fluid from women with clinical intraamniotic infection at term. *J Infect Dis.* 1982; 145:1–8. [PubMed: 7033397]
4. Romero R, Chaemsaihong P, Korzeniewski SJ, et al. Clinical chorioamnionitis at term III: how well do clinical criteria perform in the identification of proven intra-amniotic infection? *J Perinat Med.* 2016; 44:23–32. [PubMed: 25918914]
5. MacVicar J. Chorioamnionitis. *Clin Obstet Gynecol.* 1970; 13:272–290. [PubMed: 4923485]
6. Hollander D. Diagnosis of chorioamnionitis. *Clin Obstet Gynecol.* 1986; 29:816–825. [PubMed: 3545586]
7. Newton ER. Chorioamnionitis and intraamniotic infection. *Clin Obstet Gynecol.* 1993; 36:795–808. [PubMed: 8293582]
8. Tita AT, Andrews WW. Diagnosis and management of clinical chorioamnionitis. *Clin Perinatol.* 2010; 37:339–354. [PubMed: 20569811]
9. Romero R, Miranda J, Kusanovic JP, et al. Clinical chorioamnionitis at term I: microbiology of the amniotic cavity using cultivation and molecular techniques. *J Perinat Med.* 2015; 43:19–36. [PubMed: 25720095]
10. Romero R, Chaiworapongsa T, Savasan ZA, et al. Clinical chorioamnionitis is characterized by changes in the expression of the alarmin HMGB1 and one of its receptors, sRAGE. *J Matern Fetal Neonatal Med.* 2012; 25:558–567. [PubMed: 22578261]
11. Fishman SG, Gelber SE. Evidence for the clinical management of chorioamnionitis. *Semin Fetal Neonatal Med.* 2012; 17:46–50. [PubMed: 21962477]
12. Romero R, Chaemsaihong P, Korzeniewski SJ, et al. Clinical chorioamnionitis II: the intra-amniotic inflammatory response. *J Perinat Med.* 2016; 44:5–22. [PubMed: 25938217]
13. Romero R, Dey SK, Fisher SJ. Preterm labor: one syndrome, many causes. *Science.* 2014; 345:760–765. [PubMed: 25124429]
14. Duff P, Sanders R, Gibbs RS. The course of labor in term patients with chorioamnionitis. *Am J Obstet Gynecol.* 1983; 147:391–395. [PubMed: 6624808]
15. Hauth JC, Gilstrap LC 3rd, Hankins GD, et al. Term maternal and neonatal complications of acute chorioamnionitis. *Obstet Gynecol.* 1985; 66:59–62. [PubMed: 4011072]
16. Satin AJ, Maberry MC, Leveno KJ, et al. Chorioamnionitis: a harbinger of dystocia. *Obstet Gynecol.* 1992; 79:913–915. [PubMed: 1579312]
17. Mark SP, Croughan-Minihane MS, Kilpatrick SJ. Chorioamnionitis and uterine function. *Obstet Gynecol.* 2000; 95:909–912.
18. Rouse DJ, Landon M, Leveno KJ, et al. The Maternal-Fetal Medicine Units cesarean registry: chorioamnionitis at term and its duration-relationship to outcomes. *Am J Obstet Gynecol.* 2004; 191:211–216. [PubMed: 15295368]
19. Edwards RK. Chorioamnionitis and labor. *Obstet Gynecol Clin North Am.* 2005; 32:287–296. [PubMed: 15899361]
20. Yoder PR, Gibbs RS, Blanco JD, et al. A prospective, controlled study of maternal and perinatal outcome after intra-amniotic infection at term. *Am J Obstet Gynecol.* 1983; 145:695–701. [PubMed: 6829656]
21. Yancey MK, Duff P, Kubilis P, et al. Risk factors for neonatal sepsis. *Obstet Gynecol.* 1996; 87:188–194. [PubMed: 8559521]
22. Grether JK, Nelson KB. Maternal infection and cerebral palsy in infants of normal birth weight. *JAMA.* 1997; 278:207–211. [PubMed: 9218666]
23. Ladfors L, Tessin I, Mattsson LA, et al. Risk factors for neonatal sepsis in offspring of women with prelabor rupture of the membranes at 34–42 weeks. *J Perinat Med.* 1998; 26:94–101. [PubMed: 9650129]
24. Alexander JM, McIntire DM, Leveno KJ. Chorioamnionitis and the prognosis for term infants. *Obstet Gynecol.* 1999; 94:274–278. [PubMed: 10432142]
25. Wu YW, Colford JM Jr. Chorioamnionitis as a risk factor for cerebral palsy: a meta-analysis. *JAMA.* 2000; 284:1417–1424. [PubMed: 10989405]
26. Nelson KB, Willoughby RE. Infection, inflammation and the risk of cerebral palsy. *Curr Opin Neurol.* 2000; 13:133–139. [PubMed: 10987569]

27. Chaiworapongsa T, Romero R, Kim JC, et al. Evidence for fetal involvement in the pathologic process of clinical chorioamnionitis. *Am J Obstet Gynecol.* 2002; 186:1178–1182. [PubMed: 12066094]
28. Hagberg H, Wennerholm UB, Savman K. Sequelae of chorioamnionitis. *Curr Opin Infect Dis.* 2002; 15:301–306. [PubMed: 12015466]
29. Willoughby RE Jr, Nelson KB. Chorioamnionitis and brain injury. *Clin Perinatol.* 2002; 29:603–621. [PubMed: 12516738]
30. Wu YW, Escobar GJ, Grether JK, et al. Chorioamnionitis and cerebral palsy in term and near-term infants. *JAMA.* 2003; 290:2677–2684. [PubMed: 14645309]
31. Cooke R. Chorioamnionitis, maternal fever, and neonatal encephalopathy. *Dev Med Child Neurol.* 2008; 50:9. [PubMed: 18173621]
32. Blume HK, Li CI, Loch CM, et al. Intrapartum fever and chorioamnionitis as risks for encephalopathy in term newborns: a case-control study. *Dev Med Child Neurol.* 2008; 50:19–24. [PubMed: 18173624]
33. Soraisham AS, Singhal N, McMillan DD, et al. A multicenter study on the clinical outcome of chorioamnionitis in preterm infants. *Am J Obstet Gynecol.* 2009; 200:372.e1–e6. [PubMed: 19217596]
34. Shatrov JG, Birch SC, Lam LT, et al. Chorioamnionitis and cerebral palsy: a meta-analysis. *Obstet Gynecol.* 2010; 116:387–392. [PubMed: 20664400]
35. Martinelli P, Sarno L, Maruotti GM, et al. Chorioamnionitis and prematurity: a critical review. *J Matern Fetal Neonatal Med.* 2012; 25(Suppl 4):29–31. [PubMed: 22958008]
36. de Sam Lazaro S, Cheng Y, Snowden J, et al. Does the neonatal impact of chorioamnionitis in the setting of PPROM vary depending on degree of prematurity? *Am J Obstet Gynecol.* 2013; 208(Suppl):S314.
37. Garcia-Munoz Rodrigo F, Galan Henriquez GM, Ospina CG. Morbidity and mortality among very-low-birth-weight infants born to mothers with clinical chorioamnionitis. *Pediatr Neonatol.* 2014; 55:381–386. [PubMed: 24745649]
38. Uyemura A, Ameen B, Caughey A. Outcomes of chorioamnionitis in term pregnancies. *Am J Obstet Gynecol.* 2014; 210(Suppl):S215.
39. Malloy MH. Chorioamnionitis: epidemiology of newborn management and outcome United States 2008. *J Perinatol.* 2014
40. Mendez-Figueroa H, Abramovici A, O'Neil AE, et al. 647. Chorioamnionitis without and with neonatal sepsis: newborn and infant outcomes. *Am J Obstet Gynecol.* 2015; 212:S318–319.
41. Dinarello CA, Bunn PA Jr. Fever. *Semin Oncol.* 1997; 24:288–298. [PubMed: 9208885]
42. Dinarello CA. Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed. *J Endotoxin Res.* 2004; 10:201–222. [PubMed: 15373964]
43. Conti B, Tabarean I, Andrei C, et al. Cytokines and fever. *Front Biosci.* 2004; 9:1433–1449. [PubMed: 14977558]
44. Dinarello CA. Interleukin-1. *Rev Infect Dis.* 1984; 6:51–95. [PubMed: 6369481]
45. Sobrado J, Moldawer LL, Bistrian BR, et al. Effect of ibuprofen on fever and metabolic changes induced by continuous infusion of leukocytic pyrogen (interleukin 1) or endotoxin. *Infect Immun.* 1983; 42:997–1005. [PubMed: 6358043]
46. Opp MR, Krueger JM. Interleukin 1-receptor antagonist blocks interleukin 1-induced sleep and fever. *Am J Physiol.* 1991; 260:R453–457. [PubMed: 1825458]
47. Luheshi G, Miller AJ, Brouwer S, et al. Interleukin-1 receptor antagonist inhibits endotoxin fever and systemic interleukin-6 induction in the rat. *Am J Physiol.* 1996; 270:E91–95. [PubMed: 8772479]
48. Gourine AV, Rudolph K, Tesfaigzi J, et al. Role of hypothalamic interleukin-1beta in fever induced by cecal ligation and puncture in rats. *Am J Physiol.* 1998; 275:R754–761. [PubMed: 9728072]
49. Lundkvist J, Sundgren-Andersson AK, Tingsborg S, et al. Acute-phase responses in transgenic mice with CNS overexpression of IL-1 receptor antagonist. *Am J Physiol.* 1999; 276:R644–651. [PubMed: 10070123]

50. Boneberg EM, Hartung T. Febrile temperatures attenuate IL-1 beta release by inhibiting proteolytic processing of the proform and influence Th1/Th2 balance by favoring Th2 cytokines. *J Immunol.* 2003; 171:664–668. [PubMed: 12847231]
51. Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. *Immunity.* 2013; 39:1003–1018. [PubMed: 24332029]
52. Nedwin GE, Svedersky LP, Bringman TS, et al. Effect of interleukin 2, interferon-gamma, and mitogens on the production of tumor necrosis factors alpha and beta. *J Immunol.* 1985; 135:2492–2497. [PubMed: 3928750]
53. Lotze MT, Matory YL, Rayner AA, et al. Clinical effects and toxicity of interleukin-2 in patients with cancer. *Cancer.* 1986; 58:2764–2772. [PubMed: 3490903]
54. Mier JW, Vachino G, van der Meer JW, et al. Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients. *J Clin Immunol.* 1988; 8:426–436. [PubMed: 3265420]
55. Ueno Y, Takano N, Kanegane H, et al. The acute phase nature of interleukin 6: studies in Kawasaki disease and other febrile illnesses. *Clin Exp Immunol.* 1989; 76:337–342. [PubMed: 2473858]
56. LeMay LG, Vander AJ, Kluger MJ. Role of interleukin 6 in fever in rats. *Am J Physiol.* 1990; 258:R798–803. [PubMed: 2316725]
57. Cocceani F, Lees J, Mancilla J, et al. Interleukin-6 and tumor necrosis factor in cerebrospinal fluid: changes during pyrogen fever. *Brain Res.* 1993; 612:165–171. [PubMed: 8330197]
58. Chai Z, Gatti S, Toniatti C, et al. Interleukin (IL)-6 gene expression in the central nervous system is necessary for fever response to lipopolysaccharide or IL-1 beta: a study on IL-6-deficient mice. *J Exp Med.* 1996; 183:311–316. [PubMed: 8551238]
59. Cartmell T, Poole S, Turnbull AV, et al. Circulating interleukin-6 mediates the febrile response to localised inflammation in rats. *J Physiol.* 2000; 526(Pt 3):653–661. [PubMed: 10922015]
60. Dinarello CA, Bernheim HA, Duff GW, et al. Mechanisms of fever induced by recombinant human interferon. *J Clin Invest.* 1984; 74:906–913. [PubMed: 6590569]
61. Luheshi GN. Cytokines and fever. Mechanisms and sites of action. *Ann N Y Acad Sci.* 1998; 856:83–89. [PubMed: 9917868]
62. Dinarello CA, Cannon JG, Wolff SM, et al. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. *J Exp Med.* 1986; 163:1433–1450. [PubMed: 3486936]
63. Nakamura H, Seto Y, Motoyoshi S, et al. Recombinant human tumor necrosis factor causes long-lasting and prostaglandin-mediated fever, with little tolerance, in rabbits. *J Pharmacol Exp Ther.* 1988; 245:336–341. [PubMed: 3162987]
64. Morimoto A, Sakata Y, Watanabe T, et al. Characteristics of fever and acute-phase response induced in rabbits by IL-1 and TNF. *Am J Physiol.* 1989; 256:R35–41. [PubMed: 2492162]
65. Kawasaki H, Moriyama M, Ohtani Y, et al. Analysis of endotoxin fever in rabbits by using a monoclonal antibody to tumor necrosis factor (cachectin). *Infect Immun.* 1989; 57:3131–3135. [PubMed: 2777376]
66. Gay NJ, Keith FJ. Drosophila Toll and IL-1 receptor. *Nature.* 1991; 351:355–356. [PubMed: 1851964]
67. Dalpke A, Heeg K. Signal integration following Toll-like receptor triggering. *Crit Rev Immunol.* 2002; 22:217–250. [PubMed: 12498384]
68. Beutler B. Toll-like receptors: how they work and what they do. *Curr Opin Hematol.* 2002; 9:2–10. [PubMed: 11753071]
69. Leon LR. Invited review: cytokine regulation of fever: studies using gene knockout mice. *J Appl Physiol* (1985). 2002; 92:2648–2655. [PubMed: 12015385]
70. Romanovsky AA, Almeida MC, Aronoff DM, et al. Fever and hypothermia in systemic inflammation: recent discoveries and revisions. *Front Biosci.* 2005; 10:2193–2216. [PubMed: 15970487]
71. Li S, Wang Y, Matsumura K, et al. The febrile response to lipopolysaccharide is blocked in cyclooxygenase-2(–/–), but not in cyclooxygenase-1(–/–) mice. *Brain Res.* 1999; 825:86–94. [PubMed: 10216176]

72. Li S, Ballou LR, Morham SG, et al. Cyclooxygenase-2 mediates the febrile response of mice to interleukin-1 β . *Brain Res.* 2001; 910:163–173. [PubMed: 11489266]
73. Blatteis CM, Li S, Li Z, et al. Cytokines, PGE₂ and endotoxic fever: a re-assessment. *Prostaglandins Other Lipid Mediat.* 2005; 76:1–18. [PubMed: 15967158]
74. Mier JW, Souza LM, Allegretta M, et al. Dissimilarities between purified human interleukin-1 and recombinant human interleukin-2 in the induction of fever, brain prostaglandin, and acute-phase protein synthesis. *J Biol Response Mod.* 1985; 4:35–45. [PubMed: 3872345]
75. Dinarello CA, Cannon JG, Mancilla J, et al. Interleukin-6 as an endogenous pyrogen: induction of prostaglandin E₂ in brain but not in peripheral blood mononuclear cells. *Brain Res.* 1991; 562:199–206. [PubMed: 1773338]
76. Ushikubi F, Segi E, Sugimoto Y, et al. Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP₃. *Nature.* 1998; 395:281–284. [PubMed: 9751056]
77. Dinarello CA, Gatti S, Bartfai T. Fever: links with an ancient receptor. *Curr Biol.* 1999; 9:R147–150. [PubMed: 10074418]
78. Li S, Goorha S, Ballou LR, et al. Intracerebroventricular interleukin-6, macrophage inflammatory protein-1 β and IL-18: pyrogenic and PGE₂-mediated? *Brain Res.* 2003; 992:76–84. [PubMed: 14604775]
79. Ivanov AI, Romanovsky AA. Prostaglandin E₂ as a mediator of fever: synthesis and catabolism. *Front Biosci.* 2004; 9:1977–1993. [PubMed: 14977603]
80. Oka T. Prostaglandin E₂ as a mediator of fever: the role of prostaglandin E (EP) receptors. *Front Biosci.* 2004; 9:3046–3057. [PubMed: 15353336]
81. Laburn HP, Rosendorff C, Willies G, et al. Proceedings: A role for noradrenaline and cyclic AMP in prostaglandin E₁ Fever. *J Physiol.* 1974; 240:49P–50P.
82. Hou CC, Lin H, Chang CP, et al. Oxidative stress and pyrogenic fever pathogenesis. *Eur J Pharmacol.* 2011; 667:6–12. [PubMed: 21669194]
83. Lieberman E, Lang JM, Frigoletto F Jr, et al. Epidural analgesia, intrapartum fever, and neonatal sepsis evaluation. *Pediatrics.* 1997; 99:415–419. [PubMed: 9041298]
84. Gonen R, Korobochka R, Degani S, et al. Association between epidural analgesia and intrapartum fever. *Am J Perinatol.* 2000; 17:127–130. [PubMed: 11012136]
85. Goetzl L, Cohen A, Frigoletto F Jr, et al. Maternal epidural use and neonatal sepsis evaluation in afebrile mothers. *Pediatrics.* 2001; 108:1099–1102. [PubMed: 11694687]
86. Yancey MK, Zhang J, Schwarz J, et al. Labor epidural analgesia and intrapartum maternal hyperthermia. *Obstet Gynecol.* 2001; 98:763–770. [PubMed: 11704166]
87. Smulian JC, Bhandari V, Vintzileos AM, et al. Intrapartum fever at term: serum and histologic markers of inflammation. *Am J Obstet Gynecol.* 2003; 188:269–274. [PubMed: 12548228]
88. Evron S, Parameswaran R, Zipori D, et al. Activin β A in term placenta and its correlation with placental inflammation in parturients having epidural or systemic meperidine analgesia: a randomized study. *J Clin Anesth.* 2007; 19:168–174. [PubMed: 17531723]
89. Riley LE, Celi AC, Onderdonk AB, et al. Association of epidural-related fever and noninfectious inflammation in term labor. *Obstet Gynecol.* 2011; 117:588–595. [PubMed: 21343762]
90. Kovo M, Schreiber L, Ben-Haroush A, et al. Intrapartum fever at term: clinical characteristics and placental pathology. *J Matern Fetal Neonatal Med.* 2012; 25:1273–1277. [PubMed: 21992451]
91. Sharma SK, Rogers BB, Alexander JM, et al. A randomized trial of the effects of antibiotic prophylaxis on epidural-related fever in labor. *Anesth Analg.* 2014; 118:604–610. [PubMed: 24299929]
92. Gleeson NC, Nolan KM, Ford MR. Temperature, labour, and epidural analgesia. *Lancet.* 1989; 2:861–862.
93. Fusi L, Steer PJ, Maresh MJ, et al. Maternal pyrexia associated with the use of epidural analgesia in labour. *Lancet.* 1989; 1:1250–1252. [PubMed: 2566791]
94. Vinson DC, Thomas R, Kiser T. Association between epidural analgesia during labor and fever. *J Fam Pract.* 1993; 36:617–622. [PubMed: 8505604]
95. Ramin SM, Gambling DR, Lucas MJ, et al. Randomized trial of epidural versus intravenous analgesia during labor. *Obstet Gynecol.* 1995; 86:783–789. [PubMed: 7566849]

96. Mayer DC, Chescheir NC, Spielman FJ. Increased intrapartum antibiotic administration associated with epidural analgesia in labor. *Am J Perinatol.* 1997; 14:83–86. [PubMed: 9259904]
97. Sharma SK, Sidawi JE, Ramin SM, et al. Cesarean delivery: a randomized trial of epidural versus patient-controlled meperidine analgesia during labor. *Anesthesiology.* 1997; 87:487–494. [PubMed: 9316951]
98. Dashe JS, Rogers BB, McIntire DD, et al. Epidural analgesia and intrapartum fever: placental findings. *Obstet Gynecol.* 1999; 93:341–344. [PubMed: 10074975]
99. Philip J, Alexander JM, Sharma SK, et al. Epidural analgesia during labor and maternal fever. *Anesthesiology.* 1999; 90:1271–1275. [PubMed: 10319772]
100. Lucas MJ, Sharma SK, McIntire DD, et al. A randomized trial of labor analgesia in women with pregnancy-induced hypertension. *Am J Obstet Gynecol.* 2001; 185:970–975. [PubMed: 11641687]
101. Sharma SK, Alexander JM, Messick G, et al. Cesarean delivery: a randomized trial of epidural analgesia versus intravenous meperidine analgesia during labor in nulliparous women. *Anesthesiology.* 2002; 96:546–551. [PubMed: 11873026]
102. Goetzl L, Rivers J, Zighelboim I, et al. Intrapartum epidural analgesia and maternal temperature regulation. *Obstet Gynecol.* 2007; 109:687–690. [PubMed: 17329521]
103. Segal S. Labor epidural analgesia and maternal fever. *Anesth Analg.* 2010; 111:1467–1475. [PubMed: 20861420]
104. Goetzl L. Epidural analgesia and maternal fever: a clinical and research update. *Curr Opin Anaesthesiol.* 2012; 25:292–299. [PubMed: 22473213]
105. Greenwell EA, Wyshak G, Ringer SA, et al. Intrapartum temperature elevation, epidural use, and adverse outcome in term infants. *Pediatrics.* 2012; 129:e447–454. [PubMed: 22291120]
106. Arendt KW, Segal BS. The association between epidural labor analgesia and maternal fever. *Clin Perinatol.* 2013; 40:385–398. [PubMed: 23972746]
107. Goetzl L. Epidural fever in obstetric patients: it's a hot topic. *Anesth Analg.* 2014; 118:494–495. [PubMed: 24557092]
108. DiGiulio DB, Romero R, Amogan HP, et al. Microbial prevalence, diversity and abundance in amniotic fluid during preterm labor: a molecular and culture-based investigation. *PLoS One.* 2008; 3:e3056. [PubMed: 18725970]
109. DiGiulio DB, Romero R, Kusanovic JP, et al. Prevalence and diversity of microbes in the amniotic fluid, the fetal inflammatory response, and pregnancy outcome in women with preterm pre-labor rupture of membranes. *Am J Reprod Immunol.* 2010; 64:38–57. [PubMed: 20331587]
110. DiGiulio DB, Gervasi M, Romero R, et al. Microbial invasion of the amniotic cavity in preeclampsia as assessed by cultivation and sequence-based methods. *J Perinat Med.* 2010; 38:503–513. [PubMed: 20482470]
111. DiGiulio DB, Gervasi MT, Romero R, et al. Microbial invasion of the amniotic cavity in pregnancies with small-for-gestational-age fetuses. *J Perinat Med.* 2010; 38:495–502. [PubMed: 20482466]
112. Yoon BH, Romero R, Moon JB, et al. Clinical significance of intra-amniotic inflammation in patients with preterm labor and intact membranes. *Am J Obstet Gynecol.* 2001; 185:1130–1136. [PubMed: 11717646]
113. Romero R, Chaiworapongsa T, Alpay Savasan Z, et al. Damage-associated molecular patterns (DAMPs) in preterm labor with intact membranes and preterm PROM: a study of the alarmin HMGB1. *J Matern Fetal Neonatal Med.* 2011; 24:1444–1455. [PubMed: 21958433]
114. Gervasi MT, Romero R, Bracalente G, et al. Midtrimester amniotic fluid concentrations of interleukin-6 and interferon-gamma-inducible protein-10: evidence for heterogeneity of intra-amniotic inflammation and associations with spontaneous early (<32 weeks) and late (>32 weeks) preterm delivery. *J Perinat Med.* 2012; 40:329–343. [PubMed: 22752762]
115. Kim SK, Romero R, Savasan ZA, et al. Endoglin in amniotic fluid as a risk factor for the subsequent development of bronchopulmonary dysplasia. *Am J Reprod Immunol.* 2013; 69:105–123. [PubMed: 23279628]
116. Romero R, Miranda J, Chaiworapongsa T, et al. A novel molecular microbiologic technique for the rapid diagnosis of microbial invasion of the amniotic cavity and intra-amniotic infection in

- preterm labor with intact membranes. *Am J Reprod Immunol.* 2014; 71:330–358. [PubMed: 24417618]
117. Romero R, Miranda J, Chaemsaitong P, et al. Sterile and microbial-associated intra-amniotic inflammation in preterm prelabor rupture of membranes. *J Matern Fetal Neonatal Med.* 2015 Aug; 28(12):1394–409. [PubMed: 25190175]
 118. Romero R, Miranda J, Chaiworapongsa T, et al. Sterile intra-amniotic inflammation in asymptomatic patients with a sonographic short cervix: prevalence and clinical significance. *J Matern Fetal Neonatal Med.* 2014 Sep 24.:1–17. Epub ahead of print.
 119. Romero R, Miranda J, Chaiworapongsa T, et al. Prevalence and clinical significance of sterile intra-amniotic inflammation in patients with preterm labor and intact membranes. *Am J Reprod Immunol.* 2014; 72:458–474. [PubMed: 25078709]
 120. Chaemsaitong P, Romero R, Korzeniewski SJ, et al. A point of care test for the determination of amniotic fluid interleukin-6 and the chemokine CXCL-10/IP-10. *J Matern Fetal Neonatal Med.* 2015 Sep.28:1510–9. [PubMed: 25182862]
 121. Kacerovsky M, Musilova I, Andrys C, et al. Prelabor rupture of membranes between 34 and 37 weeks: the intraamniotic inflammatory response and neonatal outcomes. *Am J Obstet Gynecol.* 2014; 210:325.e1–e10. [PubMed: 24184182]
 122. Combs CA, Gravett M, Garite TJ, et al. Amniotic fluid infection, inflammation, and colonization in preterm labor with intact membranes. *Am J Obstet Gynecol.* 2014; 210:125.e1–e15. [PubMed: 24274987]
 123. Cobo T, Kacerovsky M, Jacobsson B. Amniotic fluid infection, inflammation, and colonization in preterm labor with intact membranes. *Am J Obstet Gynecol.* 2014; 211:708.
 124. Chaemsaitong P, Romero R, Korzeniewski SJ, et al. A rapid interleukin-6 bedside test for the identification of intra-amniotic inflammation in preterm labor with intact membranes. *J Matern Fetal Neonatal Med.* 2016; 29:349–59. [PubMed: 25758618]
 125. Chaemsaitong P, Romero R, Korzeniewski SJ, et al. A point of care test for interleukin-6 in amniotic fluid in preterm prelabor rupture of membranes: a step toward the early treatment of acute intra-amniotic inflammation/infection. *J Matern Fetal Neonatal Med.* 2016; 29:360–7. [PubMed: 25758620]
 126. Gibbs RS, Dinsmoor MJ, Newton ER, et al. A randomized trial of intrapartum versus immediate postpartum treatment of women with intra-amniotic infection. *Obstet Gynecol.* 1988; 72:823–828. [PubMed: 3186087]
 127. Gilstrap LC 3rd, Cox SM. Acute chorioamnionitis. *Obstet Gynecol Clin North Am.* 1989; 16:373–379. [PubMed: 2674804]
 128. Seeds JW. Impaired fetal growth: definition and clinical diagnosis. *Obstet Gynecol.* 1984; 64:303–310. [PubMed: 6379528]
 129. Alexander GR, Himes JH, Kaufman RB, et al. A United States national reference for fetal growth. *Obstet Gynecol.* 1996; 87:163–168. [PubMed: 8559516]
 130. Redline RW, Heller D, Keating S, et al. Placental diagnostic criteria and clinical correlation--a workshop report. *Placenta.* 2005; 26(Suppl A):S114–117. [PubMed: 15837060]
 131. Redline RW. Inflammatory responses in the placenta and umbilical cord. *Semin Fetal Neonatal Med.* 2006; 11:296–301. [PubMed: 16621749]
 132. Chaiworapongsa T, Erez O, Kusanovic JP, et al. Amniotic fluid heat shock protein 70 concentration in histologic chorioamnionitis, term and preterm parturition. *J Matern Fetal Neonatal Med.* 2008; 21:449–461. [PubMed: 18570125]
 133. Seong HS, Lee SE, Kang JH, et al. The frequency of microbial invasion of the amniotic cavity and histologic chorioamnionitis in women at term with intact membranes in the presence or absence of labor. *Am J Obstet Gynecol.* 2008; 199:375.e1–e5. [PubMed: 18928978]
 134. Park CW, Moon KC, Park JS, et al. The involvement of human amnion in histologic chorioamnionitis is an indicator that a fetal and an intra-amniotic inflammatory response is more likely and severe: clinical implications. *Placenta.* 2009; 30:56–61. [PubMed: 19046766]
 135. Kacerovsky M, Pliskova L, Bolehovska R, et al. The microbial load with genital mycoplasmas correlates with the degree of histologic chorioamnionitis in preterm PROM. *Am J Obstet Gynecol.* 2011; 205:213.e1–e7. [PubMed: 21663889]

136. Mi Lee S, Romero R, Lee KA, et al. The frequency and risk factors of funisitis and histologic chorioamnionitis in pregnant women at term who delivered after the spontaneous onset of labor. *J Matern Fetal Neonatal Med.* 2011; 24:37–42. [PubMed: 20698737]
137. Tsiartas P, Kacerovsky M, Musilova I, et al. The association between histological chorioamnionitis, funisitis and neonatal outcome in women with preterm prelabor rupture of membranes. *J Matern Fetal Neonatal Med.* 2013; 26:1332–1336. [PubMed: 23489073]
138. Korzeniewski SJ, Romero R, Cortez J, et al. A “multi-hit” model of neonatal white matter injury: cumulative contributions of chronic placental inflammation, acute fetal inflammation and postnatal inflammatory events. *J Perinat Med.* 2014; 42:731–743. [PubMed: 25205706]
139. Kim SM, Romero R, Park JW, et al. The relationship between the intensity of intra-amniotic inflammation and the presence and severity of acute histologic chorioamnionitis in preterm gestation. *J Matern Fetal Neonatal Med.* 2015 Sep.28:1500–1509. [PubMed: 25184305]
140. Pacora P, Chaiworapongsa T, Maymon E, et al. Funisitis and chorionic vasculitis: the histological counterpart of the fetal inflammatory response syndrome. *J Matern Fetal Neonatal Med.* 2002; 11:18–25. [PubMed: 12380603]
141. Yoon BH, Romero R, Park JS, et al. The relationship among inflammatory lesions of the umbilical cord (funisitis), umbilical cord plasma interleukin 6 concentration, amniotic fluid infection, and neonatal sepsis. *Am J Obstet Gynecol.* 2000; 183:1124–1129. [PubMed: 11084553]
142. Park JS, Romero R, Yoon BH, et al. The relationship between amniotic fluid matrix metalloproteinase-8 and funisitis. *Am J Obstet Gynecol.* 2001; 185:1156–1161. [PubMed: 11717650]
143. Yoon BH, Romero R, Shim JY, et al. C-reactive protein in umbilical cord blood: a simple and widely available clinical method to assess the risk of amniotic fluid infection and funisitis. *J Matern Fetal Neonatal Med.* 2003; 14:85–90. [PubMed: 14629087]
144. Lee SE, Romero R, Kim CJ, et al. Funisitis in term pregnancy is associated with microbial invasion of the amniotic cavity and intra-amniotic inflammation. *J Matern Fetal Neonatal Med.* 2006; 19:693–697. [PubMed: 17127492]
145. Park CW, Lee SM, Park JS, et al. The antenatal identification of funisitis with a rapid MMP-8 bedside test. *J Perinat Med.* 2008; 36:497–502. [PubMed: 19127606]
146. R Core Team. A language and environment for statistical computing. R Foundation for Statistical Computing; Vienna, Austria: 2013. <http://www.R-project.org/> [Accessed in January 2015]
147. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J R Stat Soc Series B Stat Methodol.* 1995; 57:289–300.
148. Romero R, Mazor M, Wu YK, et al. Infection in the pathogenesis of preterm labor. *Semin Perinatol.* 1988; 12:262–279. [PubMed: 3065940]
149. Romero R, Mazor M. Infection and preterm labor. *Clin Obstet Gynecol.* 1988; 31:553–584. [PubMed: 3066544]
150. Romero R, Sirtori M, Oyarzun E, et al. Infection and labor. V. Prevalence, microbiology, and clinical significance of intraamniotic infection in women with preterm labor and intact membranes. *Am J Obstet Gynecol.* 1989; 161:817–824. [PubMed: 2675611]
151. Romero R, Avila C, Santhanam U, et al. Amniotic fluid interleukin 6 in preterm labor. Association with infection. *J Clin Invest.* 1990; 85:1392–1400. [PubMed: 2332497]
152. Romero R, Avila C, Brekus CA, et al. The role of systemic and intrauterine infection in preterm parturition. *Ann N Y Acad Sci.* 1991; 622:355–375. [PubMed: 2064195]
153. Gibbs RS, Romero R, Hillier SL, et al. A review of premature birth and subclinical infection. *Am J Obstet Gynecol.* 1992; 166:1515–1528. [PubMed: 1595807]
154. Gomez R, Romero R, Edwin SS, et al. Pathogenesis of preterm labor and preterm premature rupture of membranes associated with intraamniotic infection. *Infect Dis Clin North Am.* 1997; 11:135–176. [PubMed: 9067790]
155. Romero R, Gomez R, Chaiworapongsa T, et al. The role of infection in preterm labour and delivery. *Paediatr Perinat Epidemiol.* 2001; 15(Suppl 2):41–56. [PubMed: 11520399]
156. Goncalves LF, Chaiworapongsa T, Romero R. Intrauterine infection and prematurity. *Ment Retard Dev Disabil Res Rev.* 2002; 8:3–13. [PubMed: 11921380]

157. Romero R, Espinoza J, Chaiworapongsa T, et al. Infection and prematurity and the role of preventive strategies. *Semin Neonatol.* 2002; 7:259–274. [PubMed: 12401296]
158. Romero R, Espinoza J, Goncalves LF, et al. Inflammation in preterm and term labour and delivery. *Semin Fetal Neonatal Med.* 2006; 11:317–326. [PubMed: 16839830]
159. Romero R, Espinoza J, Kusanovic JP, et al. The preterm parturition syndrome. *BJOG.* 2006; 113(Suppl 3):17–42.
160. Romero R, Gotsch F, Pineles B, et al. Inflammation in pregnancy: its roles in reproductive physiology, obstetrical complications, and fetal injury. *Nutr Rev.* 2007; 65:S194–202. [PubMed: 18240548]
161. Romero, R., Lockwood, CJ. Pathogenesis of spontaneous preterm labor. In: Creasy, RK, Resnik, R, Iams, JD, Lockwood, CJ., Moore, TR., editors. *Creasy and Resnik's maternal-fetal medicine: principles and practice.* 6. Philadelphia: Saunders Elsevier; 2009. p. 545–582.
162. Bastek JA, Gomez LM, Elovitz MA. The role of inflammation and infection in preterm birth. *Clin Perinatol.* 2011; 38:385–406. [PubMed: 21890015]
163. Agrawal V, Hirsch E. Intrauterine infection and preterm labor. *Semin Fetal Neonatal Med.* 2012; 17:12–19. [PubMed: 21944863]
164. Allen-Daniels MJ, Serrano MG, Pflugner LP, et al. Identification of a gene in *Mycoplasma hominis* associated with preterm birth and microbial burden in intra-amniotic infection. *Am J Obstet Gynecol.* 2015 Jun; 212:779.e1–e13. [PubMed: 25637842]
165. Zlatnik FJ, Cruikshank DP, Petzold CR, et al. Amniocentesis in the identification of inapparent infection in preterm patients with premature rupture of the membranes. *J Reprod Med.* 1984; 29:656–660. [PubMed: 6492031]
166. Feinstein SJ, Vintzileos AM, Lodeiro JG, et al. Amniocentesis with premature rupture of membranes. *Obstet Gynecol.* 1986; 68:147–152. [PubMed: 3737033]
167. Romero R, Quintero R, Oyarzun E, et al. Intraamniotic infection and the onset of labor in preterm premature rupture of the membranes. *Am J Obstet Gynecol.* 1988; 159:661–666. [PubMed: 3421266]
168. Mercer BM. Preterm premature rupture of the membranes. *Obstet Gynecol.* 2003; 101:178–193. [PubMed: 12517665]
169. Shim SS, Romero R, Hong JS, et al. Clinical significance of intra-amniotic inflammation in patients with preterm premature rupture of membranes. *Am J Obstet Gynecol.* 2004; 191:1339–1345. [PubMed: 15507963]
170. Santolaya-Forgas, J., Romero, R., Espinoza, J., et al. Prelabour rupture of the membranes. In: Reece, EA., Hobbins, JC., editors. *Clinical obstetrics: the fetus and mothers.* 3. Malden: Blackwell; 2008. p. 1130–1188.
171. Romero, R., Yeo, L., Gotsch, F., et al. Prelabor rupture of the membranes. In: Winn, HN, Chervanek, FA., Romero, R., editors. *Clinical maternal-fetal medicine online.* 2. London: Informa Healthcare; 2011. p. 1–24.
172. Kacerovsky M, Andrys C, Drahosova M, et al. Soluble Toll-like receptor 1 family members in the amniotic fluid of women with preterm prelabor rupture of the membranes. *J Matern Fetal Neonatal Med.* 2012; 25:1699–1704. [PubMed: 22280448]
173. Kacerovsky M, Musilova I, Khatibi A, et al. Intraamniotic inflammatory response to bacteria: analysis of multiple amniotic fluid proteins in women with preterm prelabor rupture of membranes. *J Matern Fetal Neonatal Med.* 2012; 25:2014–2019. [PubMed: 22519389]
174. Ismail AQ, Lahiri S. Management of prelabour rupture of membranes (PROM) at term. *J Perinat Med.* 2013; 41:647–649. [PubMed: 23828422]
175. Eschenbach D. Reply to: Ismail AQT, Lahiri S. Management of prelabor rupture of membranes (PROM) at term. *J Perinat Med.* 2013; 41:653–655. [PubMed: 24216161]
176. Grunebaum A. Reply to “Management of prelabour rupture of membranes (PROM) at term”. *J Perinat Med.* 2013; 41:651–652. [PubMed: 23828420]
177. Romero R, Gonzalez R, Sepulveda W, et al. Infection and labor. VIII. Microbial invasion of the amniotic cavity in patients with suspected cervical incompetence: prevalence and clinical significance. *Am J Obstet Gynecol.* 1992; 167:1086–1091. [PubMed: 1415396]

178. Lee SE, Romero R, Park CW, et al. The frequency and significance of intraamniotic inflammation in patients with cervical insufficiency. *Am J Obstet Gynecol.* 2008; 198:633.e1–8. [PubMed: 18342290]
179. Oh KJ, Lee SE, Jung H, et al. Detection of ureaplasmas by the polymerase chain reaction in the amniotic fluid of patients with cervical insufficiency. *J Perinat Med.* 2010; 38:261–268. [PubMed: 20192887]
180. Hassan SS, Romero R, Berry SM, et al. Patients with an ultrasonographic cervical length < or =15 mm have nearly a 50% risk of early spontaneous preterm delivery. *Am J Obstet Gynecol.* 2000; 182:1458–1467. [PubMed: 10871466]
181. Gomez R, Romero R, Nien JK, et al. A short cervix in women with preterm labor and intact membranes: a risk factor for microbial invasion of the amniotic cavity. *Am J Obstet Gynecol.* 2005; 192:678–689. [PubMed: 15746658]
182. Hassan S, Romero R, Hendler I, et al. A sonographic short cervix as the only clinical manifestation of intra-amniotic infection. *J Perinat Med.* 2006; 34:13–19. [PubMed: 16489881]
183. Kiefer DG, Keeler SM, Rust OA, et al. Is midtrimester short cervix a sign of intraamniotic inflammation? *Am J Obstet Gynecol.* 2009; 200:374.e1–e5. [PubMed: 19318146]
184. Vaisbuch E, Hassan SS, Mazaki-Tovi S, et al. Patients with an asymptomatic short cervix (<or=15 mm) have a high rate of subclinical intraamniotic inflammation: implications for patient counseling. *Am J Obstet Gynecol.* 2010; 202:433.e1–e8. [PubMed: 20452483]
185. Vaisbuch E, Romero R, Erez O, et al. Clinical significance of early (< 20 weeks) vs. late (20–24 weeks) detection of sonographic short cervix in asymptomatic women in the mid-trimester. *Ultrasound Obstet Gynecol.* 2010; 36:471–481. [PubMed: 20503224]
186. Elovitz MA, Wang Z, Chien EK, et al. A new model for inflammation-induced preterm birth: the role of platelet-activating factor and Toll-like receptor-4. *Am J Pathol.* 2003; 163:2103–2111. [PubMed: 14578208]
187. Wang H, Hirsch E. Bacterially-induced preterm labor and regulation of prostaglandin-metabolizing enzyme expression in mice: the role of toll-like receptor 4. *Biol Reprod.* 2003; 69:1957–1963. [PubMed: 12904319]
188. Kim YM, Romero R, Chaiworapongsa T, et al. Toll-like receptor-2 and -4 in the chorioamniotic membranes in spontaneous labor at term and in preterm parturition that are associated with chorioamnionitis. *Am J Obstet Gynecol.* 2004; 191:1346–1355. [PubMed: 15507964]
189. Mor G, Romero R, Aldo PB, et al. Is the trophoblast an immune regulator? The role of Toll-like receptors during pregnancy. *Crit Rev Immunol.* 2005; 25:375–388. [PubMed: 16167887]
190. Koga K, Cardenas I, Aldo P, et al. Activation of TLR3 in the trophoblast is associated with preterm delivery. *Am J Reprod Immunol.* 2009; 61:196–212. [PubMed: 19239422]
191. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. *Nat Immunol.* 2010; 11:373–384. [PubMed: 20404851]
192. Ilievski V, Hirsch E. Synergy between viral and bacterial toll-like receptors leads to amplification of inflammatory responses and preterm labor in the mouse. *Biol Reprod.* 2010; 83:767–773. [PubMed: 20650880]
193. Pawelczyk E, Nowicki BJ, Izban MG, et al. Spontaneous preterm labor is associated with an increase in the proinflammatory signal transducer TLR4 receptor on maternal blood monocytes. *BMC Pregnancy Childbirth.* 2010; 10:66. [PubMed: 20964862]
194. Li L, Kang J, Lei W. Role of Toll-like receptor 4 in inflammation-induced preterm delivery. *Mol Hum Reprod.* 2010; 16:267–272. [PubMed: 19995880]
195. Thaxton JE, Nevers TA, Sharma S. TLR-mediated preterm birth in response to pathogenic agents. *Infect Dis Obstet Gynecol.* 2010; 2010:378472. [PubMed: 20827416]
196. Breen K, Brown A, Burd I, et al. TLR-4-dependent and -independent mechanisms of fetal brain injury in the setting of preterm birth. *Reprod Sci.* 2012; 19:839–850. [PubMed: 22825738]
197. Kacerovsky M, Andrys C, Hornychova H, et al. Amniotic fluid soluble Toll-like receptor 4 in pregnancies complicated by preterm prelabor rupture of the membranes. *J Matern Fetal Neonatal Med.* 2012; 25:1148–1155. [PubMed: 21942553]

198. Andrys C, Kacerovsky M, Drahosova M, et al. Amniotic fluid soluble Toll-like receptor 2 in pregnancies complicated by preterm prelabor rupture of membranes. *J Matern Fetal Neonatal Med.* 2013; 26:520–527. [PubMed: 23102403]
199. Abrahams VM, Potter JA, Bhat G, et al. Bacterial modulation of human fetal membrane Toll-like receptor expression. *Am J Reprod Immunol.* 2013; 69:33–40. [PubMed: 22967004]
200. Koga K, Izumi G, Mor G, et al. Toll-like receptors at the maternal-fetal interface in normal pregnancy and pregnancy complications. *Am J Reprod Immunol.* 2014; 72:192–205. [PubMed: 24754320]
201. Romero, R., Durum, SK., Dinarello, CA. Interleukin-1: A signal for the initiation of labor in chorioamnionitis. 33rd Annual Meeting for the Society for Gynecologic Investigation; Toronto, Ontario. 1986;
202. Romero R, Brody DT, Oyarzun E, et al. Infection and labor. III. Interleukin-1: a signal for the onset of parturition. *Am J Obstet Gynecol.* 1989; 160:1117–1123. [PubMed: 2786341]
203. Romero R, Manogue KR, Mitchell MD, et al. Infection and labor. IV. Cachectin-tumor necrosis factor in the amniotic fluid of women with intraamniotic infection and preterm labor. *Am J Obstet Gynecol.* 1989; 161:336–341. [PubMed: 2764054]
204. Casey ML, Cox SM, Beutler B, et al. Cachectin/tumor necrosis factor-alpha formation in human decidua. Potential role of cytokines in infection-induced preterm labor. *J Clin Invest.* 1989; 83:430–436. [PubMed: 2913048]
205. Romero R, Parvizi ST, Oyarzun E, et al. Amniotic fluid interleukin-1 in spontaneous labor at term. *J Reprod Med.* 1990; 35:235–238. [PubMed: 2325034]
206. Romero R, Mazor M, Brandt F, et al. Interleukin-1 alpha and interleukin-1 beta in preterm and term human parturition. *American journal of reproductive immunology.* 1992; 27:117–123. [PubMed: 1418402]
207. Romero R, Tartakovsky B. The natural interleukin-1 receptor antagonist prevents interleukin-1-induced preterm delivery in mice. *Am J Obstet Gynecol.* 1992; 167:1041–1045. [PubMed: 1415389]
208. Romero R, Sepulveda W, Kenney JS, et al. Interleukin 6 determination in the detection of microbial invasion of the amniotic cavity. *Ciba Found Symp.* 1992; 167:205–220. discussion 220–223. [PubMed: 1425014]
200. Romero R, Mazor M, Sepulveda W, et al. Tumor necrosis factor in preterm and term labor. *Am J Obstet Gynecol.* 1992; 166:1576–1587. [PubMed: 1595815]
210. Hillier SL, Witkin SS, Krohn MA, et al. The relationship of amniotic fluid cytokines and preterm delivery, amniotic fluid infection, histologic chorioamnionitis, and chorioamnion infection. *Obstet Gynecol.* 1993; 81:941–948. [PubMed: 8497360]
211. Romero R, Yoon BH, Kenney JS, et al. Amniotic fluid interleukin-6 determinations are of diagnostic and prognostic value in preterm labor. *Am J Reprod Immunol.* 1993; 30:167–183. [PubMed: 8311926]
212. Romero R, Yoon BH, Mazor M, et al. The diagnostic and prognostic value of amniotic fluid white blood cell count, glucose, interleukin-6, and gram stain in patients with preterm labor and intact membranes. *Am J Obstet Gynecol.* 1993; 169:805–816. [PubMed: 7694461]
213. Saito S, Kasahara T, Kato Y, et al. Elevation of amniotic fluid interleukin 6 (IL-6), IL-8 and granulocyte colony stimulating factor (G-CSF) in term and preterm parturition. *Cytokine.* 1993; 5:81–88. [PubMed: 7683506]
214. Yoon BH, Romero R, Kim CJ, et al. Amniotic fluid interleukin-6: a sensitive test for antenatal diagnosis of acute inflammatory lesions of preterm placenta and prediction of perinatal morbidity. *Am J Obstet Gynecol.* 1995; 172:960–970. [PubMed: 7892891]
215. Arntzen KJ, Kjollesdal AM, Halgunset J, et al. TNF, IL-1, IL-6, IL-8 and soluble TNF receptors in relation to chorioamnionitis and premature labor. *J Perinat Med.* 1998; 26:17–26. [PubMed: 9595363]
216. Hsu CD, Meaddough E, Aversa K, et al. Elevated amniotic fluid levels of leukemia inhibitory factor, interleukin 6, and interleukin 8 in intra-amniotic infection. *Am J Obstet Gynecol.* 1998; 179:1267–1270. [PubMed: 9822513]

217. Athayde N, Romero R, Maymon E, et al. Interleukin 16 in pregnancy, parturition, rupture of fetal membranes, and microbial invasion of the amniotic cavity. *Am J Obstet Gynecol.* 2000; 182:135–141. [PubMed: 10649168]
218. Pacora P, Romero R, Maymon E, et al. Participation of the novel cytokine interleukin 18 in the host response to intra-amniotic infection. *Am J Obstet Gynecol.* 2000; 183:1138–1143. [PubMed: 11084555]
219. Jacobsson B, Mattsby-Baltzer I, Hagberg H. Interleukin-6 and interleukin-8 in cervical and amniotic fluid: relationship to microbial invasion of the chorioamniotic membranes. *BJOG.* 2005; 112:719–724. [PubMed: 15924526]
220. Holst RM, Laurini R, Jacobsson B, et al. Expression of cytokines and chemokines in cervical and amniotic fluid: relationship to histological chorioamnionitis. *J Matern Fetal Neonatal Med.* 2007; 20:885–893. [PubMed: 18050018]
221. Gotsch F, Romero R, Kusanovic JP, et al. The anti-inflammatory limb of the immune response in preterm labor, intra-amniotic infection/inflammation, and spontaneous parturition at term: a role for interleukin-10. *J Matern Fetal Neonatal Med.* 2008; 21:529–547. [PubMed: 18609361]
222. Marconi C, de Andrade Ramos BR, Peracoli JC, et al. Amniotic fluid interleukin-1 beta and interleukin-6, but not interleukin-8 correlate with microbial invasion of the amniotic cavity in preterm labor. *Am J Reprod Immunol.* 2011; 65:549–556. [PubMed: 21214658]
223. Kacerovsky M, Celec P, Vlkova B, et al. Amniotic fluid protein profiles of intraamniotic inflammatory response to *Ureaplasma* spp. and other bacteria. *PLoS One.* 2013; 8:e60399. [PubMed: 23555967]
224. Cobo T, Jacobsson B, Kacerovsky M, et al. Systemic and local inflammatory response in women with preterm prelabor rupture of membranes. *PLoS One.* 2014; 9:e85277. [PubMed: 24465522]
225. Romero R, Ceska M, Avila C, et al. Neutrophil attractant/activating peptide-1/interleukin-8 in term and preterm parturition. *Am J Obstet Gynecol.* 1991; 165:813–820. [PubMed: 1951537]
226. Cherouny PH, Pankuch GA, Romero R, et al. Neutrophil attractant/activating peptide-1/interleukin-8: association with histologic chorioamnionitis, preterm delivery, and bioactive amniotic fluid leukoattractants. *Am J Obstet Gynecol.* 1993; 169:1299–1303. [PubMed: 8238198]
227. Puchner T, Egarter C, Wimmer C, et al. Amniotic fluid interleukin-8 as a marker for intraamniotic infection. *Arch Gynecol Obstet.* 1993; 253:9–14. [PubMed: 8328821]
228. Dudley DJ, Trautman MS, Mitchell MD. Inflammatory mediators regulate interleukin-8 production by cultured gestational tissues: evidence for a cytokine network at the chorio-decidual interface. *J Clin Endocrinol Metab.* 1993; 76:404–410. [PubMed: 8432783]
229. Romero R, Gomez R, Galasso M, et al. Macrophage inflammatory protein-1 alpha in term and preterm parturition: effect of microbial invasion of the amniotic cavity. *Am J Reprod Immunol.* 1994; 32:108–113. [PubMed: 7826499]
230. Dudley DJ, Spencer S, Edwin S, et al. Regulation of human decidual cell macrophage inflammatory protein-1 alpha (MIP-1 alpha) production by inflammatory cytokines. *Am J Reprod Immunol.* 1995; 34:231–235. [PubMed: 8579760]
231. Cohen J, Ghezzi F, Romero R, et al. GRO alpha in the fetomaternal and amniotic fluid compartments during pregnancy and parturition. *Am J Reprod Immunol.* 1996; 35:23–29. [PubMed: 8789556]
232. Dudley DJ, Hunter C, Mitchell MD, et al. Elevations of amniotic fluid macrophage inflammatory protein-1 alpha concentrations in women during term and preterm labor. *Obstet Gynecol.* 1996; 87:94–98. [PubMed: 8532275]
233. Ghezzi F, Gomez R, Romero R, et al. Elevated interleukin-8 concentrations in amniotic fluid of mothers whose neonates subsequently develop bronchopulmonary dysplasia. *Eur J Obstet Gynecol Reprod Biol.* 1998; 78:5–10. [PubMed: 9605441]
234. Hsu CD, Meaddough E, Aversa K, et al. The role of amniotic fluid L-selectin, GRO-alpha, and interleukin-8 in the pathogenesis of intraamniotic infection. *Am J Obstet Gynecol.* 1998; 178:428–432. [PubMed: 9539502]
235. Athayde N, Romero R, Maymon E, et al. A role for the novel cytokine RANTES in pregnancy and parturition. *Am J Obstet Gynecol.* 1999; 181:989–994. [PubMed: 10521766]

236. Jacobsson B, Holst RM, Wennerholm UB, et al. Monocyte chemotactic protein-1 in cervical and amniotic fluid: relationship to microbial invasion of the amniotic cavity, intra-amniotic inflammation, and preterm delivery. *Am J Obstet Gynecol.* 2003; 189:1161–1167. [PubMed: 14586371]
237. Keelan JA, Yang J, Romero RJ, et al. Epithelial cell-derived neutrophil-activating peptide-78 is present in fetal membranes and amniotic fluid at increased concentrations with intra-amniotic infection and preterm delivery. *Biol Reprod.* 2004; 70:253–259. [PubMed: 13679321]
238. Chaiworapongsa T, Romero R, Espinoza J, et al. Macrophage migration inhibitory factor in patients with preterm parturition and microbial invasion of the amniotic cavity. *J Matern Fetal Neonatal Med.* 2005; 18:405–416. [PubMed: 16390807]
239. Esplin MS, Romero R, Chaiworapongsa T, et al. Monocyte chemotactic protein-1 is increased in the amniotic fluid of women who deliver preterm in the presence or absence of intra-amniotic infection. *J Matern Fetal Neonatal Med.* 2005; 17:365–373. [PubMed: 16009638]
240. Holst RM, Mattsby-Baltzer I, Wennerholm UB, et al. Interleukin-6 and interleukin-8 in cervical fluid in a population of Swedish women in preterm labor: relationship to microbial invasion of the amniotic fluid, intra-amniotic inflammation, and preterm delivery. *Acta Obstet Gynecol Scand.* 2005; 84:551–557. [PubMed: 15901266]
241. Hamill N, Romero R, Gotsch F, et al. Exodus-1 (CCL20): evidence for the participation of this chemokine in spontaneous labor at term, preterm labor, and intrauterine infection. *J Perinat Med.* 2008; 36:217–227. [PubMed: 18576931]
242. Cobo T, Kacerovsky M, Palacio M, et al. A prediction model of histological chorioamnionitis and funisitis in preterm prelabor rupture of membranes: analyses of multiple proteins in the amniotic fluid. *J Matern Fetal Neonatal Med.* 2012; 25:1995–2001. [PubMed: 22372866]
243. Kacerovsky M, Musilova I, Jacobsson B, et al. Cervical fluid IL-6 and IL-8 levels in pregnancies complicated by preterm prelabor rupture of membranes. *J Matern Fetal Neonatal Med.* 2015; 28:134–140. [PubMed: 24670234]
244. Kacerovsky M, Musilova I, Jacobsson B, et al. Vaginal fluid IL-6 and IL-8 levels in pregnancies complicated by preterm prelabor membrane ruptures. *J Matern Fetal Neonatal Med.* 2015; 28:392–398. [PubMed: 24754733]
245. Romero R, Emamian M, Wan M, et al. Prostaglandin concentrations in amniotic fluid of women with intra-amniotic infection and preterm labor. *Am J Obstet Gynecol.* 1987; 157:1461–1467. [PubMed: 3480691]
246. Romero R, Wu YK, Mazor M, et al. Amniotic fluid prostaglandin E2 in preterm labor. *Prostaglandins Leukot Essent Fatty Acids.* 1988; 34:141–145. [PubMed: 3222272]
247. Romero R, Wu YK, Mazor M, et al. Amniotic fluid arachidonate lipoxygenase metabolites in preterm labor. *Prostaglandins Leukot Essent Fatty Acids.* 1989; 36:69–75. [PubMed: 2788288]
248. Romero R, Mazor M, Wu YK, et al. Bacterial endotoxin and tumor necrosis factor stimulate prostaglandin production by human decidua. *Prostaglandins Leukot Essent Fatty Acids.* 1989; 37:183–186. [PubMed: 2692033]
249. Romero R, Wu YK, Hobbins JC, et al. A monokine stimulates prostaglandin-E2 production by human amnion. *Prostaglandins Leukot Essent Fatty Acids.* 1990; 41:67–69. [PubMed: 2251298]
250. Mazor M, Wiznitzer A, Maymon E, et al. Changes in amniotic fluid concentrations of prostaglandins E2 and F2 alpha in women with preterm labor. *Isr J Med Sci.* 1990; 26:425–428. [PubMed: 2401604]
251. Mitchell MD, Romero RJ, Avila C, et al. Prostaglandin production by amnion and decidual cells in response to bacterial products. *Prostaglandins Leukot Essent Fatty Acids.* 1991; 42:167–169. [PubMed: 1857723]
252. Mitchell MD, Romero RJ, Edwin SS, et al. Prostaglandins and parturition. *Reprod Fertil Dev.* 1995; 7:623–632. [PubMed: 8606975]
253. Hsu CD, Meaddough E, Aversa K, et al. Dual roles of amniotic fluid nitric oxide and prostaglandin E2 in preterm labor with intra-amniotic infection. *Am J Perinatol.* 1998; 15:683–687. [PubMed: 10333395]

254. Mikamo H, Kawazoe K, Sato Y, et al. Preterm labor and bacterial intraamniotic infection: arachidonic acid liberation by phospholipase A2 of *Fusobacterium nucleatum*. *Am J Obstet Gynecol*. 1998; 179:1579–1582. [PubMed: 9855600]
255. Hertelendy F, Rastogi P, Molnar M, et al. Interleukin-1beta-induced prostaglandin E2 production in human myometrial cells: role of a pertussis toxin-sensitive component. *Am J Reprod Immunol*. 2001; 45:142–147. [PubMed: 11270638]
256. Hertelendy F, Molnar M, Romero R. Interferon gamma antagonizes interleukin-1beta-induced cyclooxygenase-2 expression and prostaglandin E(2) production in human myometrial cells. *J Soc Gynecol Investig*. 2002; 9:215–219.
257. Mitchell MD, Chang MC, Chaiworapongsa T, et al. Identification of 9alpha,11beta-prostaglandin F2 in human amniotic fluid and characterization of its production by human gestational tissues. *J Clin Endocrinol Metab*. 2005; 90:4244–4248. [PubMed: 15840748]
258. Lee SE, Park IS, Romero R, et al. Amniotic fluid prostaglandin F2 increases even in sterile amniotic fluid and is an independent predictor of impending delivery in preterm premature rupture of membranes. *J Matern Fetal Neonatal Med*. 2009; 22:880–886. [PubMed: 19544157]
259. Maddipati KR, Romero R, Chaiworapongsa T, et al. Eicosanomic profiling reveals dominance of the epoxigenase pathway in human amniotic fluid at term in spontaneous labor. *FASEB J*. 2014; 28:4835–4846. [PubMed: 25059230]
260. Hong JS, Romero R, Lee DC, et al. Umbilical cord prostaglandins in term and preterm parturition. *J Matern Fetal Neonatal Med*. 2016; 29:523–31. [PubMed: 25758616]
261. Park JY, Ahn TG, Lee J, et al. 737: Elevated prostaglandin F2a concentration in amniotic fluid is an independent risk factor for intra-amniotic inflammation and adverse pregnancy outcome in patients with preterm labor. *Am J Obstet Gynecol*. 2015; 212:S360.
262. Athayde N, Romero R, Gomez R, et al. Matrix metalloproteinases-9 in preterm and term human parturition. *J Matern Fetal Med*. 1999; 8:213–219. [PubMed: 10475503]
263. Maymon E, Romero R, Pacora P, et al. Evidence for the participation of interstitial collagenase (matrix metalloproteinase 1) in preterm premature rupture of membranes. *Am J Obstet Gynecol*. 2000; 183:914–920. [PubMed: 11035337]
264. Maymon E, Romero R, Pacora P, et al. Evidence of in vivo differential bioavailability of the active forms of matrix metalloproteinases 9 and 2 in parturition, spontaneous rupture of membranes, and intra-amniotic infection. *Am J Obstet Gynecol*. 2000; 183:887–894. [PubMed: 11035332]
265. Maymon E, Romero R, Pacora P, et al. Human neutrophil collagenase (matrix metalloproteinase 8) in parturition, premature rupture of the membranes, and intrauterine infection. *Am J Obstet Gynecol*. 2000; 183:94–99. [PubMed: 10920315]
266. Maymon E, Romero R, Pacora P, et al. A role for the 72 kDa gelatinase (MMP-2) and its inhibitor (TIMP-2) in human parturition, premature rupture of membranes and intraamniotic infection. *J Perinat Med*. 2001; 29:308–316. [PubMed: 11565199]
267. Yoon BH, Oh SY, Romero R, et al. An elevated amniotic fluid matrix metalloproteinase-8 level at the time of mid-trimester genetic amniocentesis is a risk factor for spontaneous preterm delivery. *Am J Obstet Gynecol*. 2001; 185:1162–1167. [PubMed: 11717651]
268. Angus SR, Segel SY, Hsu CD, et al. Amniotic fluid matrix metalloproteinase-8 indicates intra-amniotic infection. *Am J Obstet Gynecol*. 2001; 185:1232–1238. [PubMed: 11717662]
269. Romero R, Chaiworapongsa T, Espinoza J, et al. Fetal plasma MMP-9 concentrations are elevated in preterm premature rupture of the membranes. *Am J Obstet Gynecol*. 2002; 187:1125–1130. [PubMed: 12439489]
270. Moon JB, Kim JC, Yoon BH, et al. Amniotic fluid matrix metalloproteinase-8 and the development of cerebral palsy. *J Perinat Med*. 2002; 30:301–306. [PubMed: 12235718]
271. Helmig BR, Romero R, Espinoza J, et al. Neutrophil elastase and secretory leukocyte protease inhibitor in prelabor rupture of membranes, parturition and intra-amniotic infection. *J Matern Fetal Neonatal Med*. 2002; 12:237–246. [PubMed: 12572592]
272. Park KH, Chaiworapongsa T, Kim YM, et al. Matrix metalloproteinase 3 in parturition, premature rupture of the membranes, and microbial invasion of the amniotic cavity. *J Perinat Med*. 2003; 31:12–22. [PubMed: 12661139]

273. Biggio JR Jr, Ramsey PS, Cliver SP, et al. Midtrimester amniotic fluid matrix metalloproteinase-8 (MMP-8) levels above the 90th percentile are a marker for subsequent preterm premature rupture of membranes. *Am J Obstet Gynecol.* 2005; 192:109–113. [PubMed: 15672011]
274. Nien JK, Yoon BH, Espinoza J, et al. A rapid MMP-8 bedside test for the detection of intra-amniotic inflammation identifies patients at risk for imminent preterm delivery. *Am J Obstet Gynecol.* 2006; 195:1025–1030. [PubMed: 17000236]
275. Kim KW, Romero R, Park HS, et al. A rapid matrix metalloproteinase-8 bedside test for the detection of intraamniotic inflammation in women with preterm premature rupture of membranes. *Am J Obstet Gynecol.* 2007; 197:292.e1–e5. [PubMed: 17826425]
276. Kim SM, Lee J, Park C, et al. One third of early spontaneous preterm delivery can be identified by a rapid matrix metalloproteinase-8 (MMP-8) bedside test at the time of mid-trimester genetic amniocentesis (abstract 556). *Am J Obstet Gynecol.* 2015; 212(Suppl):S277.
277. Park HS. The value of the genedia MMP-8 rapid test for diagnosing intraamniotic infection/inflammation and predicting adverse pregnancy outcomes in women with preterm premature rupture of membranes. *Am J Obstet Gynecol.* 2015; 212(Suppl):S174.
278. Gomez R, Romero R, Ghezzi F, et al. The fetal inflammatory response syndrome. *Am J Obstet Gynecol.* 1998; 179:194–202. [PubMed: 9704787]
279. Gotsch F, Romero R, Kusanovic JP, et al. The fetal inflammatory response syndrome. *Clin Obstet Gynecol.* 2007; 50:652–683. [PubMed: 17762416]
280. Yoon BH, Romero R, Kim KS, et al. A systemic fetal inflammatory response and the development of bronchopulmonary dysplasia. *Am J Obstet Gynecol.* 1999; 181:773–779. [PubMed: 10521727]
281. Dammann O, Leviton A. Role of the fetus in perinatal infection and neonatal brain damage. *Curr Opin Pediatr.* 2000; 12:99–104. [PubMed: 10763757]
282. Dammann O, Kuban KC, Leviton A. Perinatal infection, fetal inflammatory response, white matter damage, and cognitive limitations in children born preterm. *Ment Retard Dev Disabil Res Rev.* 2002; 8:46–50. [PubMed: 11921386]
283. Romero R, Espinoza J, Goncalves LF, et al. Fetal cardiac dysfunction in preterm premature rupture of membranes. *J Matern Fetal Neonatal Med.* 2004; 16:146–157. [PubMed: 15590440]
284. Kim YM, Romero R, Chaiworapongsa T, et al. Dermatitis as a component of the fetal inflammatory response syndrome is associated with activation of Toll-like receptors in epidermal keratinocytes. *Histopathology.* 2006; 49:506–514. [PubMed: 17064297]
285. Kim SK, Romero R, Chaiworapongsa T, et al. Evidence of changes in the immunophenotype and metabolic characteristics (intracellular reactive oxygen radicals) of fetal, but not maternal, monocytes and granulocytes in the fetal inflammatory response syndrome. *J Perinat Med.* 2009; 37:543–552. [PubMed: 19514858]
286. Malaeb S, Dammann O. Fetal inflammatory response and brain injury in the preterm newborn. *J Child Neurol.* 2009; 24:1119–1126. [PubMed: 19605775]
287. Romero R, Savasan ZA, Chaiworapongsa T, et al. Hematologic profile of the fetus with systemic inflammatory response syndrome. *J Perinat Med.* 2011; 40:19–32. [PubMed: 21957997]
288. Chaiworapongsa T, Romero R, Berry SM, et al. The role of granulocyte colony-stimulating factor in the neutrophilia observed in the fetal inflammatory response syndrome. *J Perinat Med.* 2011; 39:653–666. [PubMed: 21801092]
289. Romero R, Soto E, Berry SM, et al. Blood pH and gases in fetuses in preterm labor with and without systemic inflammatory response syndrome. *J Matern Fetal Neonatal Med.* 2012; 25:1160–1170. [PubMed: 21988103]
290. Romero R, Gomez R, Ghezzi F, et al. A fetal systemic inflammatory response is followed by the spontaneous onset of preterm parturition. *Am J Obstet Gynecol.* 1998; 179:186–193. [PubMed: 9704786]
291. Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. *Nat Rev Immunol.* 2004; 4:665–674. [PubMed: 15343366]
292. Boyman O, Cho JH, Sprent J. The role of interleukin-2 in memory CD8 cell differentiation. *Adv Exp Med Biol.* 2010; 684:28–41. [PubMed: 20795538]

293. Kalia V, Sarkar S, Subramaniam S, et al. Prolonged interleukin-2 α expression on virus-specific CD8⁺ T cells favors terminal-effector differentiation in vivo. *Immunity*. 2010; 32:91–103. [PubMed: 20096608]
294. Pipkin ME, Sacks JA, Cruz-Guilloty F, et al. Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. *Immunity*. 2010; 32:79–90. [PubMed: 20096607]
295. Pepper M, Pagan AJ, Igyarto BZ, et al. Opposing signals from the Bcl6 transcription factor and the interleukin-2 receptor generate T helper 1 central and effector memory cells. *Immunity*. 2011; 35:583–595. [PubMed: 22018468]
296. Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. *Nat Rev Immunol*. 2012; 12:180–190. [PubMed: 22343569]
297. Gaynor ER, Vitek L, Sticklin L, et al. The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells. *Ann Intern Med*. 1988; 109:953–958. [PubMed: 3264128]
298. Ognibene FP, Rosenberg SA, Lotze M, et al. Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock. *Chest*. 1988; 94:750–754. [PubMed: 3262487]
299. Hack CE, Wagstaff J, Strack van Schijndel RJ, et al. Studies on the contact system of coagulation during therapy with high doses of recombinant IL-2: implications for septic shock. *Thromb Haemost*. 1991; 65:497–503. [PubMed: 1871710]
300. Hack CE, Ogilvie AC, Eisele B, et al. C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2. *Intensive Care Med*. 1993; 19(Suppl 1):S19–28. [PubMed: 8053997]
301. Rosenstein M, Ettinghausen SE, Rosenberg SA. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. *J Immunol*. 1986; 137:1735–1742. [PubMed: 3528289]
302. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. *N Engl J Med*. 1987; 316:889–897. [PubMed: 3493432]
303. Rosenberg SA, Lotze MT, Mule JJ. NIH conference. New approaches to the immunotherapy of cancer using interleukin-2. *Ann Intern Med*. 1988; 108:853–864. [PubMed: 3285747]
304. Kovacs EJ, Brock B, Varesio L, et al. IL-2 induction of IL-1 beta mRNA expression in monocytes. Regulation by agents that block second messenger pathways. *J Immunol*. 1989; 143:3532–3537. [PubMed: 2584705]
305. Beutler B, Cerami A. Cachectin: more than a tumor necrosis factor. *N Engl J Med*. 1987; 316:379–385. [PubMed: 3543677]
306. Dinarello CA. The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome. *J Infect Dis*. 1991; 163:1177–1184. [PubMed: 2037782]
307. Thijs LG, Hack CE, Strack van Schijndel RJ, et al. Complement activation and high-dose of interleukin-2. *Lancet*. 1989; 2:395.
308. Thijs LG, Hack CE, Strack van Schijndel RJ, et al. Activation of the complement system during immunotherapy with recombinant IL-2. Relation to the development of side effects. *J Immunol*. 1990; 144:2419–2424. [PubMed: 2313099]
309. Vachino G, Gelfand JA, Atkins MB, et al. Complement activation in cancer patients undergoing immunotherapy with interleukin-2 (IL-2): binding of complement and C-reactive protein by IL-2-activated lymphocytes. *Blood*. 1991; 78:2505–2513. [PubMed: 1824247]
310. Moore FD Jr, Schoof DD, Rodrick M, et al. The systemic complement activation caused by interleukin-2/lymphokine-activated killer-cell therapy of cancer causes minimal systemic neutrophil activation. *Int J Cancer*. 1991; 49:504–508. [PubMed: 1917149]
311. Baars JW, Hack CE, Wagstaff J, et al. The activation of polymorphonuclear neutrophils and the complement system during immunotherapy with recombinant interleukin-2. *Br J Cancer*. 1992; 65:96–101. [PubMed: 1733448]
312. Sagone AL Jr, Husney RM, Triozzi PL, et al. Interleukin-2 therapy enhances salicylate oxidation by blood granulocytes. *Blood*. 1991; 78:2931–2936. [PubMed: 1954382]

313. Baars JW, de Boer JP, Wagstaff J, et al. Interleukin-2 induces activation of coagulation and fibrinolysis: resemblance to the changes seen during experimental endotoxaemia. *Br J Haematol.* 1992; 82:295–301. [PubMed: 1419810]
314. Spear ML, Stefano JL, Fawcett P, et al. Soluble interleukin-2 receptor as a predictor of neonatal sepsis. *J Pediatr.* 1995; 126:982–985. [PubMed: 7776112]
315. Delogu G, Casula MA, Mancini P, et al. Serum neopterin and soluble interleukin-2 receptor for prediction of a shock state in gram-negative sepsis. *J Crit Care.* 1995; 10:64–71. [PubMed: 7647844]
316. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. *Crit Care.* 2010; 14:R15. [PubMed: 20144219]
317. Fjell CD, Thair S, Hsu JL, et al. Cytokines and signaling molecules predict clinical outcomes in sepsis. *PLoS One.* 2013; 8:e79207. [PubMed: 24244449]
318. Dalton DK, Pitts-Meek S, Keshav S, et al. Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. *Science.* 1993; 259:1739–1742. [PubMed: 8456300]
319. Goodbourn S, Didcock L, Randall RE. Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. *J Gen Virol.* 2000; 81:2341–2364. [PubMed: 10993923]
320. Lane HC, Fauci AS. Immunologic reconstitution in the acquired immunodeficiency syndrome. *Ann Intern Med.* 1985; 103:714–718. [PubMed: 2996405]
321. Kurzrock R, Quesada JR, Rosenblum MG, et al. Phase I study of i.v. administered recombinant gamma interferon in cancer patients. *Cancer Treat Rep.* 1986; 70:1357–1364. [PubMed: 3098417]
322. Horning SJ, Levine JF, Miller RA, et al. Clinical and immunologic effects of recombinant leukocyte A interferon in eight patients with advanced cancer. *JAMA.* 1982; 247:1718–1722. [PubMed: 6174742]
323. Dinarello CA. Cytokines as endogenous pyrogens. *J Infect Dis.* 1999; 179(Suppl 2):S294–304. [PubMed: 10081499]
324. Helfgott DC, Tatter SB, Santhanam U, et al. Multiple forms of IFN-beta 2/IL-6 in serum and body fluids during acute bacterial infection. *J Immunol.* 1989; 142:948–953. [PubMed: 2536416]
325. Fong Y, Moldawer LL, Shires GT, et al. The biologic characteristics of cytokines and their implication in surgical injury. *Surg Gynecol Obstet.* 1990; 170:363–378. [PubMed: 2108507]
326. Schluter B, Konig B, Bergmann U, et al. Interleukin 6--a potential mediator of lethal sepsis after major thermal trauma: evidence for increased IL-6 production by peripheral blood mononuclear cells. *J Trauma.* 1991; 31:1663–1670. [PubMed: 1749040]
327. Akira S, Kishimoto T. IL-6 and NF-IL6 in acute-phase response and viral infection. *Immunol Rev.* 1992; 127:25–50. [PubMed: 1380488]
328. Youn YK, LaLonde C, Demling R. The role of mediators in the response to thermal injury. *World J Surg.* 1992; 16:30–36. [PubMed: 1290263]
329. Pang G, Couch L, Batey R, et al. GM-CSF, IL-1 alpha, IL-1 beta, IL-6, IL-8, IL-10, ICAM-1 and VCAM-1 gene expression and cytokine production in human duodenal fibroblasts stimulated with lipopolysaccharide, IL-1 alpha and TNF-alpha. *Clin Exp Immunol.* 1994; 96:437–443. [PubMed: 8004813]
330. Jung HC, Eckmann L, Yang SK, et al. A distinct array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion. *J Clin Invest.* 1995; 95:55–65. [PubMed: 7814646]
331. Wei SQ, Fraser W, Luo ZC. Inflammatory cytokines and spontaneous preterm birth in asymptomatic women: a systematic review. *Obstet Gynecol.* 2010; 116:393–401. [PubMed: 20664401]
332. Evers AC, Nijhuis L, Koster MP, et al. Intrapartum fever at term: diagnostic markers to individualize the risk of fetal infection: a review. *Obstet Gynecol Surv.* 2012; 67:187–200. [PubMed: 22901952]
333. Goetzl L, Evans T, Rivers J, et al. Elevated maternal and fetal serum interleukin-6 levels are associated with epidural fever. *Am J Obstet Gynecol.* 2002; 187:834–838. [PubMed: 12388959]

334. Wang LZ, Hu XX, Liu X, et al. Influence of epidural dexamethasone on maternal temperature and serum cytokine concentration after labor epidural analgesia. *Int J Gynaecol Obstet.* 2011; 113:40–43. [PubMed: 21306709]
335. Opsjln SL, Wathen NC, Tingulstad S, et al. Tumor necrosis factor, interleukin-1, and interleukin-6 in normal human pregnancy. *Am J Obstet Gynecol.* 1993; 169:397–404. [PubMed: 8362955]
336. Austgulen R, Lien E, Liabakk NB, et al. Increased levels of cytokines and cytokine activity modifiers in normal pregnancy. *Eur J Obstet Gynecol Reprod Biol.* 1994; 57:149–155. [PubMed: 7713287]
337. Arntzen KJ, Lien E, Austgulen R. Maternal serum levels of interleukin-6 and clinical characteristics of normal delivery at term. *Acta Obstet Gynecol Scand.* 1997; 76:55–60. [PubMed: 9033245]
338. Greig PC, Murtha AP, Jimmerson CJ, et al. Maternal serum interleukin-6 during pregnancy and during term and preterm labor. *Obstet Gynecol.* 1997; 90:465–469. [PubMed: 9277663]
339. Hebisch G, Grauaug AA, Neumaier-Wagner PM, et al. The relationship between cervical dilatation, interleukin-6 and interleukin-8 during term labor. *Acta Obstet Gynecol Scand.* 2001; 80:840–848. [PubMed: 11531636]
340. Malamitsi-Puchner A, Protonotariou E, Boutsikou T, et al. The influence of the mode of delivery on circulating cytokine concentrations in the perinatal period. *Early Hum Dev.* 2005; 81:387–392. [PubMed: 15814224]
341. Christiaens I, Zaragoza DB, Guilbert L, et al. Inflammatory processes in preterm and term parturition. *J Reprod Immunol.* 2008; 79:50–57. [PubMed: 18550178]
342. Unal ER, Cierny JT, Roedner C, et al. Maternal inflammation in spontaneous term labor. *Am J Obstet Gynecol.* 2011; 204:223.e1–e5. [PubMed: 21376162]
343. Cierny J, Unal E, Flood P, et al. 322. Inflammatory cytokines, fever and term labor performance. *Am J Obstet Gynecol.* 2013; 208:S144.
344. Cierny JT, Unal ER, Flood P, et al. Maternal inflammatory markers and term labor performance. *Am J Obstet Gynecol.* 2014; 210:447.e1–e6. [PubMed: 24295921]
345. Lee SE, Romero R, Jung H, et al. The intensity of the fetal inflammatory response in intraamniotic inflammation with and without microbial invasion of the amniotic cavity. *Am J Obstet Gynecol.* 2007; 197:294.e1–e6. [PubMed: 17826426]
346. Armstrong-Wells J, Donnelly M, Post MD, et al. Inflammatory predictors of neurologic disability after preterm premature rupture of membranes. *Am J Obstet Gynecol.* 2015; 212:212.e1–e9. [PubMed: 25223243]
347. Romero R, Yoon BH, Mazor M, et al. A comparative study of the diagnostic performance of amniotic fluid glucose, white blood cell count, interleukin-6, and gram stain in the detection of microbial invasion in patients with preterm premature rupture of membranes. *Am J Obstet Gynecol.* 1993; 169:839–851. [PubMed: 7694463]
348. Coultrip LL, Lien JM, Gomez R, et al. The value of amniotic fluid interleukin-6 determination in patients with preterm labor and intact membranes in the detection of microbial invasion of the amniotic cavity. *Am J Obstet Gynecol.* 1994; 171:901–911. [PubMed: 7943100]
349. Greci LS, Gilson GJ, Nevils B, et al. Is amniotic fluid analysis the key to preterm labor? A model using interleukin-6 for predicting rapid delivery. *Am J Obstet Gynecol.* 1998; 179:172–178. [PubMed: 9704784]
350. El-Bastawissi AY, Williams MA, Riley DE, et al. Amniotic fluid interleukin-6 and preterm delivery: a review. *Obstet Gynecol.* 2000; 95:1056–1064. [PubMed: 10808034]
351. Conde-Agudelo A, Papageorgiou AT, Kennedy SH, et al. Novel biomarkers for the prediction of the spontaneous preterm birth phenotype: a systematic review and meta-analysis. *BJOG.* 2011; 118:1042–1054. [PubMed: 21401853]
352. Cobo T, Kacerovsky M, Holst RM, et al. Intra-amniotic inflammation predicts microbial invasion of the amniotic cavity but not spontaneous preterm delivery in preterm prelabor membrane rupture. *Acta Obstet Gynecol Scand.* 2012; 91:930–935. [PubMed: 22524241]
353. Romero R, Kadar N, Miranda J, et al. The diagnostic performance of the Mass Restricted (MR) score in the identification of microbial invasion of the amniotic cavity or intra-amniotic

inflammation is not superior to amniotic fluid interleukin-6. *J Matern Fetal Neonatal Med.* 2014; 27:757–769. [PubMed: 24028673]

354. Vousden N, Chandiramani M, Seed P, et al. Interleukin-6 bedside testing in women at high risk of preterm birth. *J Matern Fetal Neonatal Med.* 2011; 24:1301–1304. [PubMed: 21381876]
355. Kacerovsky M, Musilova I, Hornychova H, et al. Bedside assessment of amniotic fluid interleukin-6 in preterm prelabor rupture of membranes. *Am J Obstet Gynecol.* 2014; 211:385.e1–e9. [PubMed: 24705131]
356. Berthiaume M, Rousseau E, Rola-Pleszczynski M, et al. Rapid evaluation of the absence of inflammation after rupture of membranes. *J Matern Fetal Neonatal Med.* 2014; 27:865–869. [PubMed: 23947432]
357. Lee SM, Romero R, Park JS, et al. A transcervical amniotic fluid collector: a new medical device for the assessment of amniotic fluid in patients with ruptured membranes. *J Perinat Med.* 2015; 43:381–389. [PubMed: 25372723]

Figure 1.

The maternal plasma concentrations of interleukin (IL)-2 in patients with spontaneous term labor without clinical chorioamnionitis (n=77, controls), clinical chorioamnionitis without intra-amniotic inflammation (n=8), clinical chorioamnionitis with intra-amniotic inflammation without demonstrable bacteria (n=9), and clinical chorioamnionitis with microbial-associated intra-amniotic inflammation (n=24). The median (interquartile range: IQR) maternal plasma concentrations of interleukin (IL)-2 are 0.01 (0.01–0.12) pg/mL (term in labor); 0.18 (0.14–0.24) pg/mL (clinical chorioamnionitis without intra-amniotic inflammation); 0.12 (0.05–0.14) pg/mL (clinical chorioamnionitis with intra-amniotic inflammation without demonstrable bacteria); and 0.13 (0.02–0.21) pg/mL (clinical chorioamnionitis with microbial-associated intra-amniotic inflammation). LOD, limit of detection.

Figure 2.

The maternal plasma concentrations of interferon-gamma (IFN- γ) in patients with spontaneous term labor without clinical chorioamnionitis (n=77, controls), clinical chorioamnionitis without intra-amniotic inflammation (n=8), clinical chorioamnionitis with intra-amniotic inflammation without demonstrable bacteria (n=9), and clinical chorioamnionitis with microbial-associated intra-amniotic inflammation (n=24). The median (interquartile range: IQR) maternal plasma concentrations of IFN- γ are 5.24 (3.26–8.34) pg/mL (term in labor); 88.73 (13.78–135.99) pg/mL (clinical chorioamnionitis without intra-amniotic inflammation); 6.15 (3.83–20.57) pg/mL (clinical chorioamnionitis with intra-amniotic inflammation without demonstrable bacteria); and 5.04 (3.31–7.92) pg/mL (clinical chorioamnionitis with microbial-associated intra-amniotic inflammation).

Figure 3.

The maternal plasma concentrations of interleukin (IL)-6 in patients with spontaneous term labor without clinical chorioamnionitis (n=77, controls), clinical chorioamnionitis without intra-amniotic inflammation (n=8), clinical chorioamnionitis with intra-amniotic inflammation without demonstrable bacteria (n=9), and clinical chorioamnionitis with microbial-associated intra-amniotic inflammation (n=24). The median (interquartile range: IQR) maternal plasma concentrations of IL-6 are 2.53 (1.64–4.08) pg/mL (term in labor); 6.72 (5.05–12.91) pg/mL (clinical chorioamnionitis without intra-amniotic inflammation); 9.75 (6.14–22.92) pg/mL (clinical chorioamnionitis with intra-amniotic inflammation without demonstrable bacteria); and 15.58 (5.54–22.34) pg/mL (clinical chorioamnionitis with microbial-associated intra-amniotic inflammation).

Table 1

Clinical characteristics of the study population

	Term in labor (n=77)	Clinical chorioamnionitis at term (n=41)	P value
Maternal age (years)	25 (19.5–30)	23.7 (21.6–24.6)	0.007
Body mass index (kg/m ²)	23.9 (21.3–26.1)	23.7 (21.6–24.6)	0.53
Amniotic fluid glucose (mg/dL)	N/A	9 (9–9)	N/A
Amniotic fluid white blood cell count (cell/mm ³)	N/A	58 (5–695)	N/A
Gestational age at amniocentesis (weeks)	N/A	39.6 (38.9–40.7)	N/A
Gestational age at delivery (weeks)	39.6 (38.9–40.7)	40 (39.1–40.7)	0.33
Birthweight (grams)	3450 (3200–3665)	3550 (3200–3780)	0.39

Data are presented as median (interquartile range); N/A: not applicable.

Table 2

Concentrations of maternal plasma cytokines and chemokines in term in labor vs. clinical chorioamnionitis at term

Analytes (pg/mL)	Term in labor median (IQR) (n=77)	Clinical chorioamnionitis at term median (IQR) (n=41)	Fold change	Adjusted P value
Pro-inflammatory cytokines				
IL-2	0.01 (0.01–0.12)	0.13 (0.06–0.22)	13.13	0.001
IL-6	2.53 (1.64–4.08)	10.94 (5.36–22.08)	4.32	<0.0001
IL-1 β	0.12 (0.01–0.31)	0.21 (0.11–0.34)	1.75	0.03
IL-17 α	0.55 (0.34–0.71)	0.8 (0.63–1.32)	1.45	0.002
TNF- β	0.07 (0.02–0.11)	0.1 (0.05–0.15)	1.43	0.04
TNF- α	2.06 (1.62–2.48)	2.84 (1.9–3.89)	1.38	0.008
IL-15	2.05 (1.71–2.42)	2.66 (2.25–3.67)	1.30	<0.0001
IL-12/IL-23p40	76.89 (62.43–98.69)	89.81 (70.86–112.47)	1.17	0.046
IFN- γ	5.24 (3.26–8.34)	6.15 (3.66–19.81)	1.17	0.09
IL-1 α	2.61 (1.65–4.27)	2.59 (1.94–3.52)	0.99	0.78
IL-12p70	0.07 (0.01–0.13)	0.06 (0.01–0.19)	0.86	0.24
GM-CSF	0.02 (0.02–0.09)	0.02 (0.02–0.12)	1.00	0.88
IL-16	158.99 (129.21–224.54)	173.57 (127.9–220.27)	1.10	0.93
IL-7	3.51 (2.04–6.51)	3.41 (2.15–7.64)	0.97	0.88
VEGF	14.36 (10.67–23.71)	13.48 (9.41–17.25)	0.94	0.24
Anti-inflammatory cytokines				
IL-10	0.41 (0.25–0.86)	2.04 (0.32–5)	4.97	0.0006
IL-5	0.36 (0.21–0.57)	0.48 (0.27–0.83)	1.33	0.04
IL-13	0.65 (0.28–1.01)	0.65 (0.28–1.04)	1.00	0.88
IL-4	0.03 (0.01–0.03)	0.03 (0.01–0.04)	1.00	0.97
Chemokines				
MCP-1	57.38 (51.48–70.38)	73.61 (53.78–104.7)	1.28	0.03
MIP-1 α	10.41 (7.35–12.25)	13.27 (9.29–17.36)	1.27	0.02
IL-8	3.0 (1.9–5.09)	3.67 (3.29–7.47)	1.22	0.03
Eotaxin	56.8 (43.72–77.74)	46.93 (31.29–56.09)	0.83	0.008
MCP-4	43.79 (29.91–73.38)	30.48 (24.06–43.03)	0.70	0.02

Analytes (pg/mL)	Term in labor median (IQR) (n=77)	Clinical chorioamnionitis at term median (IQR) (n=41)	Fold change	Adjusted P value
Eotaxin-3	19.36 (14.89–25.59)	4.67 (0.64–13.1)	0.24	<0.0001
MDC	520.65 (443.02–644.53)	515.51 (403.33–637.29)	0.99	0.76
CXCL-10 or IP-10	238.32 (172.2–327.48)	242.38 (179.13–485.75)	1.02	0.37
TARC	34.99 (18.74–52.3)	35.59 (22.81–52.87)	1.02	0.78
MIP-1β	59.25 (45.93–78.56)	59.33 (41.53–80.4)	1.001	0.93

CXCL-10: C-X-C motif chemokine 10; GM-CSF: granulocyte macrophage colony-stimulating factor; IFN-γ: interferon-gamma; IL: interleukin; IP-10: interferon-gamma-induced protein 10; IQR: interquartile range; MCP: monocyte chemoattractant protein; MDC: macrophage-derived chemokine; MIP: macrophage inflammatory protein; TARC: thymus and activation-regulated chemokine; TNF: tumor necrosis factor; VEGF: vascular endothelial growth factor. The units of all analytes are pg/mL.

Table 3

Concentrations of maternal plasma cytokines and chemokines in the subgroups of clinical chorioamnionitis and term in labor

Clinical chorioamnionitis at term (n=41)													
Analytes (pg/mL)	Term in labor (controls) (n=77)	without intra-amniotic inflammation (n=8)			with intra-amniotic inflammation without demonstrable bacteria (n=9)			with microbial-associated intra-amniotic inflammation (n=24)					
		Median (IQR)	Fold change (compared to term in labor)	Adjusted P-value* (compar ed to term in labor)	Median (IQR)	Fold change (compar ed to term in labor)	Adjusted P-value (compar ed to term in labor)	Adjusted P- value (compared to without intra- amniotic inflammation)	Median (IQR)	Fold change (comp ared to term in labor)	Adjusted P- value (compar ed to without intra- amniotic inflamma tion)	Adjusted P- value (compared to with intra- amniotic inflammatio n without demonstrabl e bacteria)	
Pro-inflammatory cytokines													
IL-6	2.53 (1.64–4.08)	6.72 (5.05–12.91)	2.66	0.008	9.75 (6.14–22.92)	3.85	0.009	0.78	15.58 (5.54–22.34)	6.16	<0.0001	0.70	0.92
IL-2	0.01 (0.01–0.12)	0.18 (0.14–0.24)	18.69	0.008	0.12 (0.05–0.14)	12.12	0.27	0.74	0.13 (0.02–0.21)	13.13	0.04	0.40	0.92
IFN-γ	5.24 (3.26–8.34)	88.73 (13.78–135.99)	16.93	0.008	6.15 (3.83–20.57)	1.17	0.45	0.74	5.04 (3.31–7.92)	0.96	0.82	0.08	0.87
TNF-α	2.06 (1.62–2.48)	4.46 (3.2–5.79)	2.17	0.04	2.98 (2.2–3.48)	1.45	0.05	0.74	2.42 (1.55–3.3)	1.17	0.26	0.26	0.87
IL-17α	0.55 (0.34–0.71)	1.32 (0.71–3.87)	2.40	0.04	0.83 (0.68–1.32)	1.51	0.05	0.74	0.74 (0.48–1.07)	1.35	0.09	0.40	0.87
IL-15	2.05 (1.71–2.42)	3.73 (2.93–4.51)	1.82	0.008	2.75 (2.25–3.33)	1.34	0.07	0.74	2.58 (2.23–3.18)	1.26	0.002	0.40	0.97
TNF-β	0.07 (0.02–0.11)	0.1 (0.07–0.11)	1.43	0.51	0.13 (0.08–0.15)	1.86	0.27	0.74	0.1 (0.05–0.15)	1.43	0.11	0.84	0.92
IL-12/IL-23p40	76.89 (62.43–98.69)	112.2 (87.39–147.02)	1.46	0.07	96.63 (58.76–128.84)	1.26	0.30	0.74	83.45 (70.45–101.04)	1.09	0.37	0.31	0.87
IL-16	158.99 (129.21–224.54)	118.8 (89.15–155.07)	0.75	0.13	133.63 (128.67–191.54)	0.84	0.53	0.74	187.65 (159.96–229.7)	1.18	0.31	0.26	0.87
IL-1α	2.61 (1.65–4.27)	2.65 (1.81–3.68)	1.02	0.91	2.7 (2.25–5.08)	1.03	0.53	0.74	2.57 (2.07–3.19)	0.98	0.82	1.00	0.87
GM-CSF	0.02 (0.02–0.09)	0.02 (0.02–0.13)	1.00	0.83	0.02 (0.02–0.17)	1.00	0.53	0.88	0.02 (0.02–0.06)	1.00	0.88	0.90	0.87
IL-7	3.51 (2.04–6.51)	7.79 (3.83–9.14)	2.22	0.15	4.58 (3.68–7.64)	1.3	0.27	0.74	2.72 (1.55–5.07)	0.78	0.27	0.26	0.46
IL-1β	0.12 (0.01–0.31)	0.21 (0.1–0.4)	1.79	0.32	0.31 (0.12–0.35)	2.58	0.27	0.74	0.21 (0.11–0.28)	1.71	0.11	1.00	0.87
IL-12p70	0.07 (0.01–0.13)	0.13 (0.04–0.24)	1.93	0.27	0.13 (0.04–0.21)	1.86	0.15	0.96	0.05 (0.01–0.19)	0.64	0.93	0.30	0.87
VEGF	14.36 (10.67–23.71)	13.98 (10.43–17.51)	0.97	0.61	16.8 (12.11–26.54)	1.17	0.98	0.74	12.21 (9.25–15.12)	0.85	0.19	0.84	0.87
Anti-inflammatory cytokines													
IL-10	0.41 (0.25–0.86)	1.9 (1.3–5.42)	4.63	0.02	3.19 (0.92–3.8)	7.78	0.05	0.96	1.75 (0.3–5.49)	4.27	0.05	0.70	0.95
IL-5	0.36 (0.21–0.57)	0.28 (0.2–0.47)	0.79	0.83	0.38 (0.27–0.54)	1.06	0.61	0.74	0.59 (0.4–0.91)	1.64	0.01	0.26	0.87

Clinical chorioamnionitis at term (n=41)											
Analytes (pg/mL)	without intra-amniotic inflammation (n=8)			with intra-amniotic inflammation without demonstrable bacteria (n=9)			with microbial-associated intra-amniotic inflammation (n=24)				
	Median (IQR)	Fold change (compared to term in labor)	Adjusted P- value ^a (c ompared to term in labor)	Median (IQR)	Fold change (compar ed to term in labor)	Adjusted P-value (compared to term in labor)	Adjusted P- value (compared to term in labor)	Fold change (comp ared to term in labor)	Median (IQR)	Adjusted P- value (compare d to without intra- amniotic inflamm ation)	Adjusted P- value (compared to with intra- amniotic inflammatio n without demonstrabl e bacteria)
Chemokines											
IL-4	0.03 (0.01–0.03)	0.67	0.36	0.02 (0.01–0.03)	0.67	0.81	0.74	1.00	0.03 (0.01–0.04)	0.61	0.87
IL-13	0.65 (0.28–1.01)	0.43	0.07	0.28 (0.28–0.41)	0.43	0.45	0.74	1.42	0.93 (0.28–1.37)	0.27	0.87
CXCL-10 or IP-10	238.32 (172.2–327.48)	2.11	0.02	242.6 (179.13–557.89)	1.02	0.46	0.74	0.88	209.99 (169.03–296.8)	0.70	0.87
Eotaxin-3	19.36 (14.89–25.59)	0.52	0.22	4.67 (0.64–9.54)	0.24	0.008	0.74	0.20	3.93 (0.64–12.97)	0.0003	0.92
MCP-4	43.79 (29.91–73.38)	0.76	0.50	38.85 (34.99–46.92)	0.89	0.98	0.74	0.59	26.05 (22.15–37.84)	0.003	0.41
MCP-1	57.38 (51.48–70.38)	1.65	0.07	73.01 (55.47–91.16)	1.27	0.27	0.74	1.21	69.27 (52.17–99.48)	0.26	0.92
MIP-1β	59.25(45.93–78.56)	1.16	0.29	57.28 (44.39–69.42)	0.97	0.81	0.74	1.02	60.51 (38.55–80.72)	0.82	0.92
MIP-1α	10.41 (7.35–12.25)	1.98	0.10	11.84 (8.95–13.77)	1.14	0.41	0.74	1.21	12.63 (9.4–15.2)	0.11	0.92
IL-8	3 (1.9–5.09)	1.33	0.44	3.58 (3.43–4.71)	1.19	0.27	0.96	1.20	3.61 (3.14–8.6)	0.09	0.92
TARC	34.99 (18.74–52.3)	0.77	0.50	42.57 (20.45–73.51)	1.22	0.53	0.74	1.05	36.75 (24.22–55.2)	0.61	0.92
MDC	520.65 (443.02–644.53)	1.01	0.73	463.75 (421.72–732.89)	0.89	0.98	0.78	0.98	512.05 (396.98–639.64)	0.68	0.87
Eotaxin	56.8 (43.72–77.74)	0.84	0.27	40.04 (31.29–54.04)	0.70	0.10	0.74	0.82	46.68 (32.87–57.96)	0.08	0.92

CXCL-10: C-X-C motif chemokine 10; GM-CSF: granulocyte macrophage colony-stimulating factor; IPN-γ: interferon-gamma; IL: interleukin; IP-10: interferon-gamma-induced protein 10; IQR: interquartile range; MCP: monocyte chemoattractant protein; MDC: macrophage-derived chemokine; MIP: macrophage inflammatory protein; TARC: thymus and activation-regulated chemokine; TNF: tumor necrosis factor; VEGF: vascular endothelial growth factor. The units of all analytes are pg/mL.